Lipid Regulation as a Critical Factor in the Development of Alzheimer\u27s Disease by Castello, Michael A.
Loma Linda University
TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
6-2015
Lipid Regulation as a Critical Factor in the
Development of Alzheimer's Disease
Michael A. Castello
Follow this and additional works at: http://scholarsrepository.llu.edu/etd
Part of the Medical Physiology Commons
This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative
Works. It has been accepted for inclusion in Loma Linda University Electronic Theses, Dissertations & Projects by an authorized administrator of
TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. For more information, please contact
scholarsrepository@llu.edu.
Recommended Citation
Castello, Michael A., "Lipid Regulation as a Critical Factor in the Development of Alzheimer's Disease" (2015). Loma Linda University
Electronic Theses, Dissertations & Projects. 260.
http://scholarsrepository.llu.edu/etd/260
  
 
 
 
LOMA LINDA UNIVERSITY 
School of Medicine 
in conjunction with the 
Faculty of Graduate Studies 
 
 
 
____________________ 
 
 
 
 
Lipid Regulation as a Critical Factor in the Development of 
Alzheimer’s Disease 
 
 
by 
 
 
Michael A. Castello 
 
 
 
____________________ 
 
 
 
 
A Dissertation submitted in partial satisfaction of 
the requirements for the degree 
Doctor of Philosophy in Physiology 
 
 
 
____________________ 
 
 
 
 
June 2015 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CC-BY-SA 2014 
 
Michael A. Castello 
Creative Commons Attribution-ShareAlike 4.0 International 
http://creativecommons.org/licenses/by-sa/4.0/
iii 
Each person whose signature appears below certifies that this dissertation in his/her 
opinion is adequate, in scope and quality, as a dissertation for the degree Doctor of 
Philosophy in Physiology. 
 
 
 
 
 , Chairperson 
Salvador Soriano-Castell, Associate Professor of Anatomy  
 
 
 
 
  
Jerome Badaut, Researcher, Institut de Neurosciences Cognitives et Intégratives 
d'Aquitaine  
 
 
 
  
Othman Ghribi, Associate Professor of Pharmacology, Physiology, and Therapeutics, 
University of North Dakota 
 
 
 
  
Wolff M. Kirsch, Professor of Neurosurgery 
 
 
 
 
  
William J. Pearce, Professor of Physiology 
 
iv 
ACKNOWLEDGEMENTS 
 
 
 I am extraordinarily grateful to Salvador Soriano for his mentorship and 
dedication to my development both as a scientist and as an individual; Kristy D. Howard 
for her assistance with numerous experiments as well as her encouragement; Arthur J. 
Castaneda for his work troubleshooting U18 treatment in PBMCs; John Jeppson for his 
help with biosimulation, reference finding, and reading drafts; Elizabeth Newby for 
proofreading; Kerby C. Oberg and Charmaine Pira for beta-testing; Rachel Castello for 
dry-erase outlines, joy and despair, Red Bull nights and espresso mornings. 
v 
DEDICATION 
 
 
To my wife, my family, and those who believed. I carry you in my heart. 
 
vi 
CONTENTS 
 
 
Approval Page .................................................................................................................... iii 
 
Acknowledgements ............................................................................................................ iv 
 
Dedication ............................................................................................................................v 
 
Table of Contents ............................................................................................................... vi 
 
List of Figures ......................................................................................................................x 
 
List of Tables .................................................................................................................... xii 
 
List of Abbreviations ....................................................................................................... xiii 
 
Abstract ..............................................................................................................................xv 
 
Chapter 
 
1. Introduction ..............................................................................................................1 
 
Alzheimer’s Disease in the United States ..........................................................1 
AD Characteristics .............................................................................................1 
The Amyloid Cascade Hypothesis .....................................................................2 
Shortcomings of the Amyloid Cascade Hypothesis ...........................................3 
 
Targeting Aβ Has Failed to Produce Effective AD Therapies ....................3 
Defining AD on the Basis of Aβ is Fundamentally Flawed ........................5 
Understanding Aβ Function is Critical for Understanding AD ...................9 
 
A New Direction: Moving Beyond the Amyloid Cascade ..............................10 
 
APP Functions as Part of the Brain’s Response to Stress ..........................10 
Lipid Dysregulation as a Stress and Pathogenic Trigger of Late-Onset          
AD ..............................................................................................................13 
 
Lipid Metabolism in the Brain .............................................................13 
Relationship Between Lipid Regulation and AD .................................14 
Lipid Dysregulation Insights from Niemann-Pick Type C              
Disease .................................................................................................16 
 
Cholesterol-Related Stress Drives APP Dysregulation in the             
Pathogenesis of Late-Onset AD .................................................................18 
 
vii 
Adaptive Response: A Unifying Hypothesis of Neurodegeneration ...............19 
 
Statement of Hypothesis ............................................................................19 
The Adaptive Response Hypothesis of Neurodegeneration ......................20 
 
Summary and Research Design .......................................................................25 
Specific Aim One .................................................................................25 
Specific Aim Two ................................................................................26 
Specific Aim Three ..............................................................................27 
 
2. Identification of Genes Involved in Regulation of Brain Cholesterol by         
Amyloid Precursor Protein ....................................................................................28 
 
Specific Aim One .............................................................................................28 
Introduction ......................................................................................................28 
Results ..............................................................................................................30 
 
Initial Microarray Analysis Confirms Loss of APP Affects Expression           
of Genes in Cholesterol-Related Pathways ................................................30 
 
Cholesterol-Associated Genes Differentially Expressed in the        
Absence of APP: Cerebellum ..............................................................30 
Cholesterol-Associated Genes Differentially Expressed in the        
Absence of APP: Cortex ......................................................................36 
 
IPA Analysis Connects Cholesterol Synthesis and Endocytosis          
Pathways ....................................................................................................39 
Proteomic Analysis ....................................................................................47 
 
Discussion ........................................................................................................54 
 
3. Identification of Specific Mechanisms Through Which APP Influences      
Cholesterol Homeostasis ........................................................................................58 
 
Specific Aim Two ............................................................................................58 
Introduction ......................................................................................................58 
Results ..............................................................................................................65 
 
Filipin Levels in Primary Fibroblasts ........................................................65 
Filipin Levels and Cellular Damage in Differentiated SH-SY5Y Cells ....70 
TTM Biosimulation ...................................................................................74 
 
Discussion ........................................................................................................78 
 
Filipin Fluorescence Correlates with Disease Severity .............................79 
viii 
27-OHC Treatment Produces AD-Like Filipin Fluorescence in    
Differentiated SH-SY5Y Cells ..................................................................79 
Biosimulation Validates Impact of APP Loss on Cholesterol          
Metabolism ................................................................................................80 
 
4. Confirmation of Clinical Relevance and Practical Application of APP-       
Cholesterol Relationships in the Brain ..................................................................85 
 
Specific Aim Three ..........................................................................................85 
Introduction ......................................................................................................85 
Results ..............................................................................................................87 
 
Filipin Levels in Human Brains .................................................................87 
Cholesterol Dysregulation in Peripheral Blood Mononuclear Cells..........88 
Myo-Parkinson’s Project ...........................................................................93 
 
Discussion ........................................................................................................96 
 
5. Discussion ..............................................................................................................98 
 
APP is a Regulator of Brain Cholesterol Homeostasis ..................................100 
Direct Clinical Application of Findings .........................................................103 
Supporting the Adaptive Response Hypothesis .............................................104 
Concluding Remarks ......................................................................................107 
 
6. Materials and Methods .........................................................................................108 
 
Introduction ....................................................................................................108 
Cell Culture ....................................................................................................108 
 
Human Fibroblasts and B-Lymphocytes .................................................108 
Peripheral Blood Mononuclear Cells .......................................................110 
SH-SY5Y Cells ........................................................................................110 
 
Immunofluorescence ......................................................................................111 
 
Preparation of Filipin ...............................................................................111 
Filipin Staining for FACS Analysis .........................................................111 
Filipin Staining of Human Tissue ............................................................111 
Filipin staining and Immunofluorescence for Microscropy .....................112 
 
Flow Cytometry .............................................................................................112 
Microarray Analysis .......................................................................................113 
Transcriptome-to-Metabolome Biosimulation...............................................113 
 
Initial Simulations ....................................................................................113 
ix 
Simulation Refinement ............................................................................114 
  
Preparation of Protein Lysates .......................................................................115 
 
Tissue Lysis .............................................................................................115 
Cell Lysis .................................................................................................115 
Proteomic Analysis ........................................................................................116 
 
Trypsin Digestion and Isotope Labeling ..................................................116 
Strong Cation Exchange Fractionation ....................................................116 
Desalting ..................................................................................................117 
Result Analysis ........................................................................................117 
 
Statistical Analysis .........................................................................................118 
U18666A and Cholesterol Treatment ............................................................118 
 
Chemical Preparation ...............................................................................118 
Cytotoxicity Assay ...................................................................................119 
 
Western Blotting ............................................................................................119 
 
References ........................................................................................................................120 
 
Appendices 
 
A. Patent Filings ....................................................................................................143 
 
Methods and Kits for Determining Risk for Developing                    
Alzheimer’s Disease and Prevention or Treatment Thereof ....................143 
Tremor Detection and Correction System ...............................................153 
 
B. Publications .......................................................................................................136 
 
Rational Heterodoxy: Cholesterol Reformation of the Amyloid       
Doctrine....................................................................................................172 
On the Origin of Alzheimer’s Disease. Trials and Tribulations of                 
the Amyloid Hypothesis ..........................................................................180 
Filipin Levels as Potential Predictors of Alzheimer’s Disease                  
Risk ..........................................................................................................184 
x 
FIGURES 
 
Figures Page 
 
1. Comparison of Amyloid and Adaptive Response Hypotheses ................................7 
2. Visual Representation of the Adaptive Response Hypothesis ...............................24 
3. Reelin-Related Interactions in Three Mouse Genotypes .......................................40 
4. Consequences of APP Loss on Lipid Regulation Pathways. .................................42 
5. Network Map of CD59 Relationships ....................................................................44 
6. Network Map of ERMN-Related Genes ................................................................46 
7. Relative GAPDH Expression .................................................................................53 
8. In Vitro Testing of APP Mechanisms. ...................................................................60 
9. Fibroblast Western Blots ........................................................................................66 
10. Filipin Staining of NPC Fibroblasts .......................................................................68 
11. Filipin Staining of AD Fibroblasts .........................................................................69 
12. Effect of Oxysterols on Cell Survival and Filipin Staining ...................................72 
13. Cholesterol Biosynthesis in Appko Mice ................................................................75 
14. Cholesterol Biosynthesis in Npc1-/- Mice ..............................................................76 
15. Cholesterol Biosynthesis in Appko/Npc1-/- Mice .....................................................77 
16. Simplified Cholesterol Biosynthesis in Appko mice ...............................................82 
17. TTM Biosimulation Uncovers Possible Experimental Approaches ......................84 
18. Cholesterol Dysregulation in Human PBMCs .......................................................89 
xi 
19. Filipin Staining of B-Lymphocytes .......................................................................91 
20. Concept for Detection of Movement Abnormalities Using Myo Device ..............95 
21. Results from Testing the Adaptive Response Hypothesis ...................................106 
 
xii 
TABLES 
 
 
Tables Page 
 
1. Genes of Interest Differentially Expressed in Mouse Cerebellum Samples ..........32 
2. Genes of Interest Differentially Expressed in Mouse Cortex Samples ..................38 
3. Representative Sample of Proteomics Data. .................................................... 50-52 
4. List of Cells Purchased from Coriell Cell Repository .........................................109 
xiii 
ABBREVIATIONS 
 
 
AD    Alzheimer’s disease 
NFT    Neuroibrilary tangles 
Aβ    Amyloid beta peptide 
SP    Senile plaques 
APP    Amyloid Precursor Protein 
NPC1    Neimann-Pick type C disease gene 1 
NPC    Neimann-Pick type C disease 
SDS    Sodium dodecyl sulfate 
TBS    Tris-buffered saline 
T-TBS    1% Triton X-100 in tris-buffered saline 
IPA    Ingenuity Pathway Analysis 
DTT    Dithiothreitol 
TEAB    Triethylammonium buffer 
FA    Formic acid 
AcN    Acetonitrile 
KCl    Postassium chloride 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
ROS    Reactive oxygen species 
NADPH   Nicotinamide adenine dinucleotide phosphate 
TTM    Transcriptome-to-Metabolome biosimulation algorithm 
COPASI   COmplex PAthway SImulator 
NodeXL   Network Overview, Discovery, and Exploration for Excel 
xiv 
GWAS   Genome-wide association study 
24-OHC   24-hydroxycholesterol 
27-OHC   27-hydroxycholesterol 
PBMCs   Peripheral blood mononuclear cells 
PFA    Paraformaldehyde 
U18    U18666A compound  
FACS    Fluorescence-activated cell sorting 
RT    Room temperature 
EDTA    Ethylenediaminetetraacetic acid 
ACK    Ammonium-chloride-potassium lysing buffer 
RA    Retinoic acid 
BNDF    Brain-derived neurotrophic factor 
LDH    Lactate dehydrogenase 
LXR    Liver x receptor 
CTF    C-terminal fragment 
 
xv 
ABSTRACT OF THE DISSERTATION 
Lipid Regulation as a Critical Factor in the Development of 
Alzheimer’s Disease  
 
by 
 
Michael. A. Castello 
Doctor of Philosophy, Graduate Program in Physiology 
Loma Linda University, June 2015 
Dr. Salvador Soriano-Castell, Chairperson 
 
Alzheimer’s disease (AD) is the most common form of dementia in the United 
States, representing around eighty percent of all cases. For more than two decades, 
researchers have been led by the amyloid cascade hypothesis, which assumes that 
accumulation of the amyloid peptide Aβ, derived by proteolytic processing from the 
amyloid precursor protein (APP), is the key pathogenic trigger in AD. To date, therapies 
have largely focused on removing Aβ from the brain, an approach that has produced 
disappointing clinical outcomes. 
I present an alternative hypothesis in which Aβ production and aggregation is a 
symptom of a larger, systemic disease affecting the regulation of lipids, including 
cholesterol. In addition to assigning a physiological function for APP and Aβ generation, 
my hypothesis suggests that lipid dysregulation would likely occur early in the disease 
process, making it an ideal target for identification of disease risk or even intervention. 
Using a mouse model, I show that expression of APP is involved in the regulation 
of cholesterol synthesis, endocytosis, and myelination pathways. Using human cell 
culture models, I demonstrate that fibroblasts and peripheral blood mononuclear cells 
taken from AD patients show signs of lipid dysregulation, and that neuron-like cells 
xvi 
develop this dysregulation when exposed to oxysterols. Finally, I developed and 
characterized a method of quantifying these detrimental changes using a fluorescence 
compound, filipin, which could form the basis of a commercial test to evaluate the 
potential risk of conversion from mild cognitive impairment to AD. 
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CHAPTER ONE 
INTRODUCTION 
 
Alzheimer’s Disease in the United States 
Alzheimer’s disease (AD) is the most common form of dementia in the United 
States, representing around eighty percent of all cases. As the country’s sixth leading 
cause of death, AD currently affects 5.4 million Americans, a figure that translates to one 
in eight people age 65 or older and nearly half of Americans over 85 (Alzheimer’s 
Association 2013). While deaths from well-known diseases such as HIV, stroke, and 
heart disease have decreased over the past decade, AD deaths continue to increase, 
incurring an estimated annual cost of $183 billion. As the US population ages, the 
number of individuals with AD is projected to increase to 7.7 million over the next 
twenty years (Alzheimer’s Association 2013). Despite years of research, AD continues to 
have no cure or effective treatments. 
 
AD Characteristics 
Clinically, AD begins with difficulty remembering names and events. Later stages 
feature symptoms such as confusion and difficulty walking and swallowing, eventually 
ending in death. Affirmative diagnosis of the disease is only possible at autopsy, when 
specific pathological hallmarks can be visualized in the brain: extracellular deposits 
termed senile plaques (SPs), comprised of the amyloid-beta peptide (Aβ), and 
neurofibrillary tangles (NFTs), made from abnormally phosphorylated tau protein.  
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Aβ is 38 to 43 amino acids in length, formed through sequential cleavage of the 
amyloid precursor protein (APP) by β- and γ-secretases (J. Hardy and Selkoe 2002). The 
40 (Aβ40) and 42 (Aβ42) amino acid forms are the most abundant, the latter having the 
greater tendency to aggregate (Jarrett, Berger, and Lansbury 1993). 
NFTs are formed when the tau protein is abnormally phosphorylated and 
aggregates into paired helical fragments (Grundke-Iqbal et al. 1986). Tau is a cytoskeletal 
protein with a key role in axonal transport; formation of NFTs disrupts this transport and 
structurally disables neurons, leading to cell loss, cognitive decline, and patient death 
(Roy et al. 2005). 
 
The Amyloid Cascade Hypothesis 
Characterization of the process by which Aβ is produced from APP led Hardy, 
Higgins, and Selkoe to propose linking SPs and NTFs in the initial form of the Amyloid 
Cascade Hypothesis (J. A. Hardy and Higgins 1992). The hypothesis states that the 
pathogenic process of AD initiates upon accumulation, oligomerization, and aggregation 
of Aβ in SPs. Aβ accumulation subsequently promotes the hyperphosphorylation of tau 
protein, leading to formation of NFTs and neurodegeneration, causing the pathological 
presentation and dementia symptoms (J. A. Hardy and Higgins 1992; D J Selkoe 1991). 
The overwhelming majority of research in the field has been driven by this premise, 
which has held a firm grip on the field since AD research began gaining momentum in 
the 90s (Karran, Mercken, and Strooper 2011; Karran and Hardy 2014). 
When the amyloid hypothesis was formed, strong evidence appeared to support its 
assumptions. All forms of the rare (representing approximately 1% of AD cases) familial 
early-onset AD are linked to specific mutations in APP or its cleavage enzymes that 
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promote increased Aβ production (Alzheimer’s Association 2013; Hendriks et al. 1992; 
Scheuner et al. 1996; Goate et al. 1991; Mullan et al. 1992). Trisomy 21 (Down 
syndrome, DS) usually results in three copies of the APP gene and formation of Aβ 
plaques identical to those found in AD patients (Masters et al. 1985). Since both FAD 
and DS exhibit pathology clearly linked to Aβ production, it seems reasonable to 
conclude that late onset AD – which also has abnormal Aβ – must also begin with Aβ. 
Thus, the amyloid cascade hypothesis implicates overproduction and aggregation of Aβ 
as the most likely cause of observed neurodegeneration in late onset AD, FAD, and DS, a 
pathological process that is accelerated in FAD and DS due to genetically abnormal APP. 
Subsequently, the amyloid cascade hypothesis has been supported by innumerable animal 
and cell culture studies in which pathology is induced by Aβ and rescued by its removal 
(Jin et al. 2011; Li, Ebrahimi, and Schluesener 2013; Bloom 2014; Bignante et al. 2013). 
Focusing primarily on these findings, the thinking currently guiding clinical trials 
concludes that removing Aβ from the brain is the expedient strategy for the treatment of 
AD.  
 
Shortcomings of the Amyloid Cascade Hypothesis 
Targeting Aβ Has Failed to Produce Effective AD Therapies 
Despite initial optimism, attempts to cure or slow progression of AD by targeting 
Aβ have resulted in an ever-growing list of miscarriages. Guided by the amyloid cascade 
hypothesis, some of the first AD drugs to reach clinical trial targeted Aβ production by 
inhibiting the enzymes involved in its generation (β- or γ-secretases), or by driving γ-
secretase activity toward the production of shorter, less aggregation-prone forms of Aβ in 
lieu of A42. More recently, strategies have included the inhibition of Aβ aggregation or 
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enhancing mechanisms of Aβ removal, the most promising of these being Aβ removal via 
the passive induction of an anti-Aβ immune response. Discouragingly, all of these 
therapeutic approaches have had a negligible effect on cognitive functioning – even when 
successfully reducing “Aβ load” in the brain – and in some cases have even accelerated 
disease progression (Karran, Mercken, and Strooper 2011; Benilova, Karran, and De 
Strooper 2012; R. A. Sperling, Jack, and Aisen 2011; Mullard 2012; Aisen, Vellas, and 
Hampel 2013; Golde, Petrucelli, and Lewis 2010; Vellas 2010; S. Salloway et al. 2011; 
Doody et al. 2014; Stephen Salloway et al. 2014; Karran and Hardy 2014). Throughout 
its lifespan, the immune approaches have been limited by the unintended consequences of 
increased vascular Aβ deposition and edema, both features of the common AD 
comorbidity cerebral amyloid angiopathy (CAA) in which vascular Aβ deposition leads 
to edema, hemorrhage, and increased cell loss (C. Holmes et al. 2008; Delrieu et al. 2011; 
Karran and Hardy 2014; Stephen Salloway et al. 2014; R. Sperling et al. 2012; M. Zabel 
et al. 2013; Cupino and Zabel 2014). 
As trial after trial has failed, culling the once-promising roster of therapeutic 
approaches, several of the highest profile remainders are representatives of the passive 
immunotherapy approach: anti-Aβ antibodies bapineuzumab and solanezumab. However, 
according to reports published in the New England Journal of Medicine, even these 
heavyweights appear destined to disappoint. Phase 3 clinical trials of both drugs have 
failed to improve clinical outcomes in patients with late onset AD, with bapineuzumab 
treatment continuing to be limited by edema formation (Doody et al. 2014; Stephen 
Salloway et al. 2014; Karran and Hardy 2014). Rather than prompting a critical re-
examination of the amyloid hypothesis, clinical trial frustrations have been attributed not 
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to shortcomings in the hypothesis, but to weaknesses in the experimental design:  patients 
are treated too late in the disease process for drugs to be effective, damage is caused by 
undetectable Aβ oligomers prior to plaque formation, or the wrong patients have been 
selected for treatment (Karran and Hardy 2014; Benilova, Karran, and De Strooper 2012; 
Castellani and Smith 2011; Castello and Soriano 2014). Unfortunately, this line of 
reasoning overlooks numerous other observations collected since the amyloid hypothesis 
was first proposed that contradict its assumptions for treatment and the definition of AD 
itself. 
 
Defining AD on the Basis of Aβ is Fundamentally Flawed 
A major contribution to the continued failure of anti-Aβ clinical trials is that 
affirmative diagnosis of AD can only occur when the presence of Aβ accumulation in the 
brain is confirmed, a definition contradicted by an increasing amount of data (Castello 
and Soriano 2013). Imaging studies confirm previous post-mortem observations of Aβ 
accumulation in a significant proportion of non-demented individuals (Jack et al. 2013; 
Hulette et al. 1998; Aizenstein H et al. 2008; Price et al. 2009; Crystal et al. 1988). 
Conversely, a sizable proportion of patients clinically diagnosed with AD do not display 
Aβ accumulation–even though neurodegeneration is in progress (Jack et al. 2013; Hyman 
et al. 2012). Based on this information, many in the medical community have concluded 
that Aβ status is not a reliable marker for the early stages of clinical AD, instead relying 
more heavily on neurological function in diagnosis (Jack et al. 2013; Hyman et al. 2012; 
Dubois et al. 2010). Remarkably, AD researchers have instead reached a consensus in 
which clinically diagnosed AD patients without Aβ accumulation are classified as not 
suffering from AD. Other than Aβ, there is no evidentiary basis for the assumption that 
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clinical AD cases with and without Aβ accumulation are etiologically different. Such 
reasoning effectively perpetuates a tautological argument in which an a priori assumption 
that Aβ is the cause of AD is used to reject any clinical case in which no Aβ increase is 
apparent. 
This defective logic, employed by many involved in AD research and clinical 
trials, is further illustrated by figure 1. Cognitive status assessment and Aβ imaging data 
lead, according to the amyloid hypothesis, to a division of the population into four 
distinct groups (Fig 1A), which are: patients who are cognitively healthy (normal 
cognition, NC; Fig 1A, 4), patients who are cognitively healthy but accumulate Aβ 
(normal cognition with Aβ, NC-Aβ; Fig 1A, 2), patients with neurodegeneration who 
have clinical AD symptoms but no Aβ accumulation (neurodegeneration-first AD, NDF-
AD; Fig 1A, 3), and finally, patients who have neurodegeneration, clinical AD 
symptoms, and Aβ accumulation (Aβ-first AD, AF-AD; Fig 1A, 5) (Karran and Hardy 
2014; Jack et al. 2013; Hyman et al. 2012). According to the amyloid hypothesis, of all 
four observed populations, only those with Aβ-first AD can be considered by definition 
as suffering from AD, and only the group with normal cognition and no Aβ should be 
considered as appropriate cognitively normal controls in clinical trials. This is the 
reasoning used in the EXPEDITION 3 phase of the ongoing solanezumab trial to justify 
the exclusion of approximately 25% of patients in the study – all of whom were clinically 
diagnosed with mild AD, but whose imaging data showed no Aβ accumulation (Doody et 
al. 2014; Karran and Hardy 2014). 
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Figure 1. Comparison of Amyloid and Adaptive Response Hypotheses. A, Amyloid 
Hypothesis. Cognitive tests and amyloid imaging separate the total population into four 
distinct groups (1).  These groups are: Normal Cognition (NC; 4), NC with Aβ 
accumulation (NC-Aβ; 2), Neurodegeneration-First AD (NDF-AD; 3), and Amyloid-First 
AD (AF-AD; 5). Under this hypothesis, only the AF-AD and NC groups (4,5) are going 
to be studied moving forward in EXPEDITION 3 as disease state and control, whereas 
the NC-Aβ and NDF-AD groups (2,3) are ignored, as they cannot be explained and do 
not fit the paradigm. B, Adaptive Response Hypothesis. The total population (1) is 
differentiated by a set of stress variables (2) which may include, but are not limited to, 
oxidative stress, metabolism dysregulation (cholesterol homeostasis, insulin resistance, 
etc.), genetic factors, and inflammatory response. These variables elicit an adaptive 
response in the brain and, depending on the nature and intensity of such response, the 
population falls into two groups, either Normal Cognition (NC) (3) or AD (4), both of 
which contain Aβ positive and negative subpopulations. 
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Logically, a decision to exclude patients in this manner is inconsistent with the 
available data. It has been known for some time that Aβ plaques do not correlate with 
areas of neurodegeneration, which is why the amyloid hypothesis implicates soluble Aβ 
oligomers as the cause of AD (Terry et al. 1991; Dickson et al. 1995; Walsh et al. 2002; 
Dennis J Selkoe 2008; Knopman et al. 2003; Heiko Braak and Del Tredici 2011). 
Solanezumab is thought to remove these soluble oligomers, yet plaques are the only form 
of Aβ detectable by imaging methods (Holland et al. 2014; Esparza et al. 2012). There is 
no obvious reason to continue to follow and treat patients in whom Aβ plaques are 
already detectable, since the presence of those plaques occurs too late in the disease for 
anti-Aβ treatment to be effective (S. Salloway et al. 2011; Golde, Schneider, and Koo 
2011; Karran and Hardy 2014). By eliminating patients diagnosed with clinical AD who 
lack Aβ plaques, all patients in early stages of neurodegeneration that would potentially 
benefit from the solanezumab trial have effectively been removed. 
Some scientists attempting to abandon the Aβ-centric view of AD by focusing on 
the tau protein in NFTs nonetheless fall into identical thought patterns. “Amyloid 
hypothesis” reasoning has been offered for a tau hypothesis in which 
hyperphosphorylated tau protein replaces Aβ as the pathogenic trigger of AD, perhaps by 
acting as a prion protein to spread its aggregation-prone structure from neuron to neuron 
(Heiko Braak and Del Tredici 2011). There has been a rush to develop antibodies to 
aggressively remove “toxic” tau, in the hope that by doing so AD progression will be 
slowed or halted (Yanamandra et al. 2013). As with the Aβ trials, these studies are 
defeated before they begin. At this point it seems increasingly unlikely that targeting 
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proteins for removal from the brain is a viable method of attacking AD. Instead, AD 
treatments will need to address the disease process as part of the wider brain physiology. 
 
Understanding Aβ Function is Critical for Understanding AD 
Following the reasoning of the amyloid hypothesis, every in vitro and in vivo 
experimental model of AD begins with overexpression of Aβ itself (Jin et al. 2011; Li, 
Ebrahimi, and Schluesener 2013; Bloom 2014; Bignante et al. 2013). Ostensibly, these 
models validate the hypothesis by demonstrating harm when Aβ is overproduced and 
subsequent improvement when it is removed; however, while all cases of FAD can be 
linked to a relatively small number of mutations directly affecting APP processing, this is 
not the case with late-onset AD (J. A. Hardy and Higgins 1992; Blennow, de Leon, and 
Zetterberg 2006). Because FAD only represents approximately 1% of all AD cases, it is 
more likely that its unique Aβ-producing mutations represent a subset of possible 
pathways for developing AD, rather than a mechanistic model of the late onset disease 
affecting the vast majority of AD patients (Alzheimer’s Association 2013; Hendriks et al. 
1992; Scheuner et al. 1996). In the largest analyses of late-onset AD to date, nearly all of 
the genetic polymorphisms most frequently observed occur in genes associated with 
cholesterol metabolism, endocytosis (an essential part of cholesterol processing), and 
inflammation (Naj et al. 2011; Bali et al. 2012; Hollingworth et al. 2011). Along with 
studies showing that Aβ accumulation has little relationship to AD initiation or 
symptoms, this evidence strongly argues against Aβ as a suitable therapeutic target or 
even as a reliable marker for defining the disease (Hulette et al. 1998; Aizenstein H et al. 
2008; Hyman et al. 2012; Jack et al. 2013; Knopman et al. 2003; H Braak and Braak 
1991). Unfortunately, by considering Aβ a toxic byproduct of APP metabolism, the 
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amyloid cascade hypothesis offers little insight into the physiological generation of Aβ. 
Neither the physiological role of Aβ nor the mechanisms of its accumulation are well 
understood and without this information, we will not be able to explain why A is 
generated in the healthy brain, let alone place it within the pathological process of AD. 
 
A New Direction: Moving Beyond the Amyloid Cascade 
New, evidence-based thinking is needed to replace the Aβ-focused model 
provided by the amyloid cascade hypothesis, a perspective that begins by considering Aβ 
as a protein with a physiological function whose production from APP is, like other 
cellular processes, susceptible to dysregulation. As is the case with inflammation or cell 
division, Aβ production can be both necessary and harmful, and the logical way for 
potential harm to be assuaged is to strive to understand its purpose – beginning with its 
parent, APP. Lamenting the slow progress of AD research, John Hardy, one of the initial 
proponents of the amyloid hypothesis, stated that “If I was a young researcher now, I 
would try to work out what the function of APP is (J. Hardy and Mayer 2011).” Despite 
the wealth of data on the cellular and molecular mechanisms of APP trafficking and 
processing into Aβ, the primary function of APP in the brain remains unknown. 
 
APP Functions as Part of the Brain’s Response to Stress 
Several hypotheses that are not Aβ-centric have been proposed, although few 
have gained significant traction (Obrenovich et al. 2002; Castellani et al. 2009; Castellani 
and Smith 2011; H. Lee et al. 2007; Benilova, Karran, and De Strooper 2012; Marchesi 
2011). Unlike in the past, however, numerous independent researchers have now gathered 
sufficient information to strongly support a reworked conceptualization of late onset AD. 
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Synthesizing this information, I propose that Aβ accumulates as part of a response to 
chronic brain stress stimuli (Castello and Soriano 2013; Castello and Soriano 2014). 
These stress stimuli constitute the bona fide pathogenic triggers of late onset AD and, 
therefore, would be suitable candidates for therapeutic intervention (Herrup 2010b; 
Castello and Soriano 2013; Castello and Soriano 2014; Castellani and Smith 2011; 
Stranahan and Mattson 2012). That vision can be understood in the context of hormesis, 
the idea that the brain benefits greatly from low levels of cognitive or physical stress that 
elicit a response from biological repair systems (Stranahan and Mattson 2012). “Common 
sense” interventions, such as exercise, aid successful brain aging by stimulating the 
brain’s adaptive response mechanisms, promoting restorative activity that otherwise 
would not occur (Stranahan and Mattson 2012). In this scenario, the presence of 
excessive Aβ is evidence of an ongoing stress process, rather than a marker of disease 
initiation as the amyloid hypothesis assumes. 
Applying this model to AD, as illustrated in figure 1B, the total population (Fig 
1B, 1) can be affected by chronic stress stimuli (Fig 1B, 2) which may include, but are 
not limited to, oxidative stress, metabolic dysregulation (cholesterol homeostasis, insulin 
resistance, etc.), genetic factors, and inflammatory response (Castello and Soriano 2014; 
Stranahan and Mattson 2012). Each of these stimuli is capable of eliciting a response in 
which Aβ is produced, and the nature of that response (not the total amount of Aβ that 
may accumulate in parallel) determines progression into clinical AD (Castello and 
Soriano 2013; Castello and Soriano 2014). Ultimately this leads to the observed division, 
shown in figure 1B, into individuals with normal cognition (NC; Fig 1B, 3) and those 
clinically diagnosed with AD (AD; Fig 1B, 4), both of which may be further divided into 
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Aβ positive and Aβ negative subpopulations (Castello and Soriano 2013; Castellani and 
Smith 2011). According to this view, therapeutic approaches must address the biology of 
the chronic stressors that initiate the disease, not the Aβ accumulation that, unlike in 
FAD, may or may not occur. This offers numerous potential avenues to explore in the 
battle against AD. In fact, research into aging, cholesterol regulation, and metabolic 
disorders such as diabetes all can potentially be applied to AD. Conceiving of the disease 
in this open-ended, systemic fashion will allow clinicians and scientists to identify new 
patterns and possibilities for therapy. 
In further support of this view, acute stress such as traumatic brain injury causes 
an increase in Aβ production that is inversely correlated with hyperphosphorylated tau 
(the basis of NFTs) and signs of neuronal injury (Magnoni et al. 2012; Tsitsopoulos and 
Marklund 2013). A similar effect is observed after ischemia, possibly in response to high 
oxidative stress (Pluta et al. 2013). Even low levels of stress can promote a response from 
APP, with synaptic activity producing Aβ, and APP itself aiding in plasticity and axon 
pruning (Bero et al. 2011; Cirrito et al. 2005; Hoe et al. 2009; Nikolaev et al. 2009). 
Other stressors likely include metabolism and cholesterol regulation, which would 
account for the significantly increased risk of AD in individuals with the less-efficient ε4 
allele of the cholesterol transporter apolipoprotein E (ApoE) (Corder et al. 1993; Akram 
et al. 2010). Diabetes symptomatology also significantly accelerates both Aβ and tau 
pathology in a mouse model of aging, while systematic cholesterol dysregulation directly 
alters tau in the absence of APP (Currais et al., 2012; Nunes et al., 2011). If Aβ is 
produced from APP as part of its involvement in the brain’s adaptive response to stress, it 
is easy to see how Aβ accumulation may (but not necessarily) occur over time both in 
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successful aging and in parallel with disease progression, in accordance with what has 
been clinically observed in elderly patients. 
 
Lipid Dysregulation as a Stress and Pathogenic Trigger of Late-Onset AD 
Lipid Metabolism in the Brain 
Although the human brain accounts for 2% of body mass, it contains about 25% 
of total body cholesterol (Chobanian and Hollander 1962). In cells, membrane cholesterol 
is concentrated in the lipid rafts, with lower levels present in the intracellular membranes 
of organelles (Simons and Ikonen 1997; Schroeder et al. 2001; Reitz 2013). Lipids, such 
as cholesterol and sphingolipids, appear to be tightly regulated in the brain, with APP and 
its cleavage products, including Aβ, acting through multiple functional pathways to 
maintain balance (Grimm, Zimmer, et al. 2013). It is well documented that cholesterol, 
for example, is a key regulator of cellular processes in the brain, including the formation 
of myelin sheaths, synaptic function, membrane fluidity and neurosteroid biosynthesis; 
cholesterol homeostasis has also been linked to learning and memory function in both 
humans and animals (Chris M. Valdez et al. 2010; Schreurs 2010). 
Cholesterol turnover in the brain is slow, with a half-life of five years in humans 
and four to six months in rodents (I. Björkhem et al. 1998; Sérougne-Gautheron and 
Chevallier 1973; Bogdanovic et al. 2001; Ingemar Björkhem and Meaney 2004). Due to 
blood-brain barrier separation, most brain cholesterol is synthesized endogenously in 
glial cells and astrocytes, with a smaller portion occurring in neurons (M. Saito et al. 
1987; Chris M. Valdez et al. 2010). Cholesterol synthesis begins with the conversion of 
coenzyme A (CoA) into 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) in the cytoplasm 
(Tymoczko and Stryer 2002). In the ER, HMG-CoA is converted into mevalonate by 
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HMG-CoA reductase (HMGCR), from mevalonate into 5-phospho-mevalonate by 
mevalonate kinase, and from 5-phospho-mevalonate to cholesterol by 7-
dehydrocholesterol reductase (7-DHCR) (Tymoczko and Stryer 2002). Because HMGCR 
catalyzes the rate-limiting step, it is highly regulated by feedback inhibition: high 
cholesterol levels trigger HMGCR ubiquitination and degradation by the proteosome, 
while low cholesterol levels stimulate sterol regulated element binding protein (SREBP) 
to promote HMGCR transcription (Canevari and Clark 2007). Cholesterol synthesized in 
astrocytes is attached to apolipoprotein E (ApoE) and secreted as high-density lipoprotein 
particles, which are taken up by neurons via the endosomal-lysosomal system and 
recycled to the plasma membrane or delivered to other organelles (Wahrle et al. 2004; 
Brown and Goldstein 1986; Benarroch 2008). Cholesterol is removed from the brain by 
first being converted into oxysterols, which are capable of crossing the blood-brain 
barrier; once in the periphery oxysterols are metabolized by the liver (I. Björkhem et al. 
1998). 
 
Relationship between Lipid Regulation and AD 
Lipids appear to be highly dysregulated in AD, suggesting the kind of chronic 
stress environment that could cause APP to continuously produce Aβ (Wells et al. 1995; 
Lars Svennerholm, Boström, and Jungbjer 1997; Prasad et al. 1998). While physiological 
cholesterol synthesis rates and levels in the healthy brain decline more than 40% with 
age, reflecting the different needs and roles for brain cholesterol at different stages of life, 
this phenotype is reversed in late-onset AD (Thelen et al. 2006). At the same time, 
membrane lipids involved in myelination are decreased (Lars Svennerholm, Boström, and 
Jungbjer 1997; L. Svennerholm and Gottfries 1994). Furthermore, there is a strong 
15 
correlation between levels of brain cholesterol and disease severity in the AD brain 
(Phelix et al. 2011). 
Studies of APP physiology also support cholesterol-related stress as a key 
causative factor in the pathogenesis of the disease. Processing of APP into Aβ occurs in 
the cholesterol-rich lipid rafts, and cholesterol accumulation can enlarge lipid raft size, 
thereby increasing A generation (Cordy et al. 2003; M. Burns et al. 2003; O. Holmes et 
al. 2012). Because of this, it is possible for cholesterol dysregulation to occur prior to, 
and increase, Aβ production, a concept supported by animal studies in which rabbits and 
APP transgenic mice fed a cholesterol-enriched diet showed increases in A(Sparks et 
al. 2000; Shie et al. 2002; Ghribi et al. 2006). Conversely, α-cleavage of APP, which 
prevents APP from producing Aβ,  is increased in the presence of polyunsaturated fatty 
acids; in mice, dietary stigmasterol reduces the cholesterol composition of lipid rafts and 
decreases β-cleavage (Grimm, Haupenthal, et al. 2013; Burg et al. 2013). Anomalies in 
cholesterol levels and distribution are able to influence the phosphorylation state of tau 
and create NFTs independently of A (Q. Liu et al. 2010; Koudinov and Koudinova 
2001; Nunes et al. 2011). Taken together, this means that cholesterol is capable of 
inducing the production of Aβ (and its aggregation into SPs) and the formation of NFTs 
independently of the Aβ-tau cascade mechanism proposed by the amyloid hypothesis. As 
previously mentioned, there is also a well-established link between AD and ApoE, a 
protein that, in the brain, is involved in transporting cholesterol and other lipids (Bu 
2009). Individuals homozygous for the ε4 allele of the APOE gene, which produces a 
protein product that is a less efficient transporter than its counterparts, are as much as 18-
fold more likely to develop AD (Corder et al. 1993). More recent genetic evidence in 
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support of cholesterol dysregulation as causative of late-onset AD has been provided by 
genome-wide association studies (GWAS). Remarkably, in addition to APOE, four other 
genes are associated with cholesterol metabolism and/or transport: CLU, ABCA7, LDLR, 
SORL1 (Hollingworth et al. 2011; Naj et al. 2011; Jones et al. 2010). A second 
associated pathway is that of endocytosis, also linked to cholesterol biology 
(Hollingworth et al. 2011; Jones et al. 2010; Naj et al. 2011). In that respect, the gene 
PICALM is of particular interest, as it has been shown to confer risk predominantly in the 
presence of APOE 4 positive subjects (Jun et al. 2010). TP53INP1, a stress-inducible 
protein that mediates apoptotic cell death, and SUCLG2, involved in metabolism via the 
citric acid cycle, are also risk factors for AD (Escott-Price et al. 2014; Ramirez et al. 
2014). 
 
Lipid Dysregulation Insights from Niemann-Pick Type C Disease 
Other neurodegenerative conditions can also be informative with regards to a 
potential causative role for cholesterol in brain pathogenesis.  Of particular interest is the 
lysosomal storage disorder Niemann-Pick type C disease (NPC). In NPC, mutations in 
either of two genes, NPC1 and NPC2, results in intracellular accumulation of unesterified 
cholesterol and other lipids in late endosomes and lysosomes across all cell types (Lloyd-
Evans and Platt 2010; Vance 2006). In the brain, NPC causes dendritic and axonal 
abnormalities and neuronal death (particularly Purkinje cells in the cerebellum); patients 
present with splenomegaly, abnormal movement, seizures, and dementia (Ory 2004; 
Vance 2006). 
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In common with AD, APP is disproportionately metabolized to A in NPC, even 
forming AD-like plaques in patients carrying the ApoE 4 allele; tau has been observed 
both in early stages of hyper-phosphorylation and as NFTs that are indistinguishable from 
those appearing in AD brains (Y. Saito et al. 2002; Auer et al. 1995; Treiber-Held et al. 
2003). NFTs are also more readily detectable in cell populations most affected by 
cholesterol accumulation, often forming without any prior deposition of A into plaques, 
indicative of a direct causative link between cholesterol dysregulation and NFT formation 
(Love, Bridges, and Case 1995; Treiber-Held et al. 2003). Increased expression of NPC1 
has been reported in cortex and hippocampus from AD patients, and some NPC1 
polymorphisms have been linked to increased risk of developing AD (Kågedal et al. 
2010; Rodríguez-Rodríguez et al. 2010). Loss of one copy of the NPC1 gene in AD mice 
harboring PS1 and APP mutations leads to accelerated A42 accumulation, compared to 
control mice with two copies of NPC1 (Borbon and Erickson 2011). 
Healthy functioning of the brain appears to depend heavily on lipid regulation – a 
process that is markedly dysregulated in AD. Sustained dysregulation of brain lipids, 
such as cholesterol, could play a key role in beginning the pathological processes that 
lead to AD. Not only does cholesterol have the ability to directly impact Aβ production 
and tau aggregation, a significant number of genes involved in cholesterol homeostasis 
are associated with AD. Other neurodegenerative conditions such as NPC provide formal 
proof that cholesterol dysregulation can precede, and lead to, Aand tau abnormalities 
similar to those commonly observed in AD. If these relationships between APP and lipid 
regulation are functional, rather than merely coincidental, they would support a model in 
which AD is a consequences of sustained activation of the brain’s adaptive response to 
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stress. If this is the case, identifying and treating these stressors would be a far more 
effective avenue for AD therapy than targeting its symptoms, such as Aβ production. 
 
Cholesterol-Related Stress Drives APP Dysregulation in the 
Pathogenesis of Late-Onset AD 
As previously mentioned, the biological function of APP in the brain is not well 
understood, in particular with regards to the physiological generation of A and the 
mechanisms leading to its accumulation. An alternative to the amyloid cascade 
hypothesis should provide new areas for research and potential therapy by attempting to 
explain the role of APP and A in both health and disease. I have suggested that the 
evidence accumulated to date indicates that APP functions to regulate lipid homeostasis 
in the brain in response to stress, through mechanisms including, but not limited to, A 
generation. 
The evidence in support of APP as a lipid regulator in the brain is multifold. In rat 
neurons, APP has been shown to regulate endogenous cholesterol synthesis via the rate-
limiting enzyme, HMG CoA reductase (HMGCR), with decreased cholesterol turnover 
leading to inhibition of neuronal activity (Pierrot et al. 2013). In a mouse model of NPC 
that faithfully recreates the disease phenotype and cholesterol accumulation observed in 
human patients, loss of APP leads to an exacerbation of the cholesterol abnormalities 
seen in NPC brains, which in turn leads to accelerated progression of the disease 
(Treiber-Held et al. 2003; Nunes et al. 2011).  
APP contains a cholesterol-sensing domain shown to be functional in vitro, 
thereby providing a potential molecular mechanism by which APP could be involved in 
regulation of brain cholesterol through HMGR, LRP1, and other cholesterol-associated 
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pathways (Barrett et al. 2012; Beel et al. 2010; Beel et al. 2008). The cleavage products 
of APP have been shown to directly affect lipid regulation pathways. Cholesterol 
synthesis is increased by α-cleaved APP, a product of APP cleavage that does not 
produce Aβ (Grimm, Grimm, and Hartmann 2007). This APP product may even be 
involved in extracellular signaling by selectively binding to phosphoinositides (PIPs) in 
the lipid rafts of neurons, which would make it highly sensitive to PIP levels (Dawkins et 
al. 2014). A acts to reduce the size of lipid rafts by decreasing sphingomyelin and 
inhibiting cholesterol synthesis by HMGR (Grimm et al. 2005; Grimm, Grimm, and 
Hartmann 2007; Wang et al. 2014). Interestingly, neprilysin, a major protein responsible 
for degrading Aβ, is decreased in both level and activity in AD patients (Grimm, Mett, et 
al. 2013). The remaining APP intracellular domain (AICD) acts as a transcription factor 
to suppress production of the cholesterol transporter LRP1 (Q. Liu et al. 2007). 
Furthermore, A production is increased in response to 27-hydroxycholesterol (27-
OHC), an oxidized, neurotoxic form of cholesterol that is increased in AD brains 
(Shafaati et al. 2011; Jaya R. P. Prasanthi et al. 2011).  
 
Adaptive Response: A Unifying Hypothesis of Neurodegeneration 
Statement of Hypothesis 
Collectively, the evidence described above leads me to propose the hypothesis 
that 
Lipid dysregulation is a key stressor in the early pathogenesis of AD, and APP 
metabolism – including Aβ production – is part of an adaptive response to stress in the 
brain. 
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A corollary to this hypothesis is that heritable mutations cause early-onset AD by 
dysregulating the adaptive response. 
 
The Adaptive Response Hypothesis of Neurodegeneration 
In this hypothesis, illustrated in figure 2, AD occurs as a result of long-term stress 
that is capable of overwhelming the defense mechanisms in the brain. Because APP 
functions as part of the defense mechanisms, stress factors, including lipid dysregulation, 
are the more likely bona fide pathogenic triggers in AD – rather than arbitrary A 
accumulation. Stresses to the brain can originate from numerous sources: physical 
trauma, illness, metabolic stress, vascular pathology, genetic polymorphisms, even 
regular neuronal activity (Herrup 2010b; J.-P. Liu et al. 2010; Sato et al. 2012; Jaya R. P. 
Prasanthi et al. 2011; Kirsch et al. 2003; Mattson 2009; Stranahan et al. 2011; Xu et al. 
2011; Stranahan and Mattson 2012; Suzuki et al. 2010; Bero et al. 2011; Castellani et al. 
2009; Castellani and Smith 2011; Castello and Soriano 2013; Castello and Soriano 2014; 
Brody et al. 2008). Whether benign or severe, these stressors provoke a response from 
APP as part of the brain’s defense mechanisms (Herrup 2010b; Stranahan and Mattson 
2012). APP responds to stress by producing α-cleavage or β-cleavage products, which act 
in signaling pathways, as transcription factors, or to regulate other proteins (Magnoni et 
al. 2012; Tsitsopoulos and Marklund 2013; Pluta et al. 2013; Bero et al. 2011; Cirrito et 
al. 2005; Hoe et al. 2009; Akram et al. 2010; Hölscher 2011).  Lipid regulation is 
particularly sensitive to stress, exhibiting changes in levels, localization, or oxidation that 
both cause inflammation and provoke a response from APP (J.-P. Liu et al. 2010; Sato et 
al. 2012; Jaya R. P. Prasanthi et al. 2011; Kirsch et al. 2003; Mattson 2009; Stranahan et 
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al. 2011; Xu et al. 2011; van den Kommer et al. 2009). Importantly, the presence of Aβ 
and inflammation in this scenario is evidence of an ongoing stress process, rather than a 
marker of disease initiation, explaining why Aβ plaques are found in many cognitively 
normal patients. As long as the response remains functional, the stress is alleviated and 
homeostasis in the brain is restored. This has been observed in traumatic brain injury, 
where Aβ is inversely correlated with increased tau pathology as neurological status 
improves – perhaps due to increased synaptic activity (Brody et al. 2008; Magnoni et al. 
2012).  
Sustained stress can overwhelm the adaptive response, causing it to remain active 
despite being insufficient to counteract the imbalances. It is likely that numerous genetic 
and environmental factors affect the brain’s ability to resist stress before the adaptive 
response transitions from functional to dysfunctional, which would explain why brain 
injury, diabetes, the ε4 allele of ApoE, polymorphisms in lipid regulation genes, and 
microglial clearance of Aβ can all increase risk for later development of AD (Magnoni 
and Brody 2010; Bennett et al. 2013; Conejero-Goldberg et al. 2011; Hölscher 2011; 
Cheng et al. 2011; Naj et al. 2011; Hollingworth et al. 2011; M. Zabel et al. 2013). In the 
dysfunctional response, Aβ continues to be produced and can aggregate into oligomers 
and plaques, where it affects already-vulnerable neurons by perpetuating inflammation, 
extending oxidative damage, and contributing to tau hyperphosphorylation and 
aggregation (Morgan 2009).  
A dysfunctional response contributes to a disease state in which the brain 
experiences major cellular damage as a consequence of destructive inflammation, axonal 
transport disruption, tau phosphorylation and aggregation, reactive oxygen species, and 
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neuronal commitment to aberrant entry into the cell cycle – all of which have been shown 
to occur as a consequence of unchecked lipid dysregulation (Thirumangalakudi et al. 
2008; Pappolla et al. 2002; Stranahan et al. 2011; M. Zhang et al. 2010; Nunes et al. 
2011; Koudinov and Koudinova 2001; Conejero-Goldberg et al. 2011; Currais, 
Hortobágyi, and Soriano 2009; Herrup 2010a). Once in the disease state, inflammation 
can have additional destructive effects on lipid regulation (Block and Hong 2005). 
Vascular A deposition would be prominent at this stage, contributing to cerebral 
amyloid angiopathy (CAA) and microbleeds. A plausible mechanism for cholesterol-
induced cell cycle reentry in AD involves miR-33, a microRNA encoded within SREBP-
2 that is involved in the regulation of cholesterol synthesis and uptake, as well as the 
expression of cell cycle genes – including cyclin D1 (Mandas et al. 2012; Cirera-Salinas 
et al. 2012). Specifically, downregulation of miR-33 leads to increased cyclin D1 levels, 
and could conceivably result in neuronal reentry into the cell cycle (Cirera-Salinas et al. 
2012; Currais, Hortobágyi, and Soriano 2009). SREBP-2, which interacts with APP 
cleavage products, is downregulated in AD; since miR-33 levels mirror those of SREBP-
2, the resulting increase in cyclin D1 would contribute to an aberrant entry into the cell 
cycle (Mandas et al. 2012; Bommer and MacDougald 2011; Wang et al. 2014). 
Ultimately, the disease state results in synaptic collapse, loss of dendritic mass, and 
neuronal destruction that causes dementia and death (Arendt 2009; Uylings and de 
Brabander 2002). 
Figure 2 also emphasizes the fundamental differences between early-onset AD, 
Down syndrome, and late-onset AD. In the former two cases, Aβ is constitutively 
overproduced throughout life (or the A42/A40 ratio is significantly higher), in the 
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absence of stress to cholesterol regulation. In such instances, the protective role of APP 
metabolites in the brain is not available, and the sustained overexpression of A 
accelerates the rate at which cell dysfunction occurs, through a combination of a weaker 
adaptive response and a lower threshold for transition from functional to dysfunctional 
response. Neurodegeneration is further exacerbated by the impact of a higher A load on 
the pathogenic cascade. 
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Figure 2. Visual Representation of the Adaptive Response Hypothesis. Through various 
factors including metabolism, trauma, and synaptic activity, the environment produces 
stress on the brain. Stress promotes a response from APP and inflammatory processes 
that can be both functional and dysfunctional. A functional response corrects the stress, 
while a dysfunctional response contributes to a disease state in which continuous 
activation of the response system leads to tau tangles, cell cycle reentry, and Aβ 
deposition, ultimately resulting in cell death. Any stage of this process can be affected by 
genetics. 
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Summary and Research Design 
Several decades of research have failed to produce effective treatments for AD. 
Based on the amyloid cascade hypothesis, which implicates Aβ production and 
aggregation as causative to AD, numerous potential therapies have advanced to clinical 
trial only to demonstrate negligible benefit to AD sufferers (J. A. Hardy and Higgins 
1992; Mullard 2012; Karran and Hardy 2014; Karran, Mercken, and Strooper 2011). 
Such failures highlight a major shortcoming of the amyloid cascade hypothesis: it ignores 
any possible physiological function for Aβ. Aβ is cleaved from the larger precursor 
protein, APP, a molecule relevant to cholesterol regulation (Nunes et al. 2011; Barrett et 
al. 2012; Kosicek et al. 2010) Synthesizing this information, I proposed the adaptive 
response hypothesis, which suggests that APP is centrally involved in brain lipid 
regulation, especially in response to stress (Castello and Soriano 2013). In fulfillment of 
my PhD requirements, I proposed to experimentally test my hypothesis through three 
specific aims, the results of which are discussed in the following three chapters.  
 
Specific Aim One 
To identify genes involved in brain cholesterol homeostasis that are regulated by 
the amyloid precursor protein, APP, I performed genetic microarray analysis of 
cerebellum and cortex collected from pre-symptomatic mice of the following genotypes: 
non-functional NPC1 (Npc1-/-); lack of APP (Appko); double mutant carrying non-
functional NPC1 and lacking APP (Appko/Npc1-/-), and wildtype controls. Microarray 
changes were validated by proteomic analysis using a shotgun approach.  
In my original proposal, I planned to validate microarray changes at the RNA and 
protein level using real-time quantitative PCR and Western blotting, respectively. 
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However, these approaches were replaced by proteomics as this technique could 
potentially measure protein-level changes across thousands of proteins simultaneously. 
Specific Aim One is discussed in Chapter Two. 
 
Specific Aim Two 
To identify specific mechanisms through which APP influences cholesterol 
homeostasis, I developed an in silico model in which to measure the systemic impact of 
manipulating APP on the cholesterol homeostasis pathways identified in SA1. Because 
entire molecular pathways can be observed in silico, this technique will reduce 
dependency on both in vitro and in vivo models for observation of system-wide 
consequences of genetic changes. 
In my original proposal, I also planned to use primary fibroblasts from NPC and 
AD patients and age-matched controls as an in vitro approach to study the role of APP on 
cholesterol homeostasis. However, in the process of establishing the model, I discovered 
that the intensity of filipin staining in NPC cells appeared to correlate with the severity of 
the NPC case, and that AD fibroblasts displayed increased baseline filipin staining 
relative to their age-matched controls. 
These findings suggested to me that filipin could be a marker of both cellular 
damage and disease status. Furthermore, if cellular damage, as detected by filipin, were 
to begin at presymptomatic stages of AD, and its severity were to increase with disease 
progression, it might be possible to differentiate mild cognitive impairment (MCI) 
sufferers according to their risk of conversion into AD by monitoring filipin staining. 
Consequently, I moved away from the original idea of using primary fibroblasts to test 
the in vitro role of APP in cholesterol homeostasis and explored instead the link between 
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filipin fluorescence and cellular damage, to obtain proof of concept that filipin is not only 
associated with an increase in cholesterol levels, but also can be a measure of cellular 
damage and, by extension, of disease status.  
In summary, my second specific aim consists of the in vitro characterization of 
the link between filipin staining and cellular damage, as well as the generation of a 
biosimulation model to identify pathway-wide mechanisms through which APP 
influences cholesterol homeostasis. Specific Aim Two is discussed in Chapter Three. 
 
Specific Aim Three 
To determine if filipin levels can be used as potential predictors of Alzheimer’s 
disease risk, I tested whether filipin intensity correlates with dementia status in peripheral 
blood mononuclear cells and B-lymphocytes obtained from AD patients. In my initial 
proposal, I planned to investigate the relevance of the results obtained in SA1 and SA2 to 
human AD by measuring levels and tissue distribution of proteins, identified in the 
previous two aims as associated with APP function, in human autopsy brain samples. 
However, the in vitro findings in SA2 lead to a more sophisticated implementation of this 
aim, in which I now lay the foundation for a larger-scale clinical study of filipin-
detectable cellular cholesterol abnormalities as a predictor of AD risk. This work 
confirms that my hypothesis and work in model systems is relevant to clinical AD while 
also having potential diagnostic utility. The practical and clinical work involved in these 
experiments was instrumental in the creation and patenting of two diagnostic tests for 
AD, both of which have detailed roadmaps for clinical validation in the near future. 
Specific Aim Three is discussed in Chapter Four. 
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CHAPTER TWO 
IDENTIFICATION OF GENES INVOLVED IN REGULATION OF 
BRAIN CHOLESTEROL BY AMYLOID PRECURSOR PROTEIN 
 
Specific Aim One 
To identify genes involved in brain cholesterol homeostasis that are regulated by 
the amyloid precursor protein, APP, I performed genetic microarray analysis of 
cerebellum and cortex collected from pre-symptomatic mice of the following genotypes: 
non-functional NPC1 (Npc1-/-); lack of APP (Appko); double mutant carrying non-
functional NPC1 and lacking APP (Appko/Npc1-/-), and wildtype controls. Microarray 
changes were validated by proteomic analysis using a shotgun approach.  
 
Introduction 
Initial work by Nunes et al has demonstrated the importance of APP in a mouse 
model of severe cholesterol dysregulation (Nunes et al. 2011). While the impact of 
removing APP from healthy mice includes modest age-dependent cognitive and 
locomotor deficits, reactive gliosis, and synaptic degeneration, APP loss in NPC1 mice 
results in an exacerbation of their aberrant cholesterol phenotype (Zelcer et al. 2009; 
Kang and Fölsch 2011). These double mutant mice show decreased myelination and 
impaired cholesterol trafficking (Nunes et al. 2011). These findings suggest that APP has 
a specific role in the metabolism, transport, and/or usage of cholesterol in the brain – 
collectively defined as cholesterol regulation. I propose that this role is likely to be part of 
29 
an adaptive response to stress, such that if cholesterol function is not impaired, APP is 
not necessary and its loss would have a negligible impact. Thus, the NPC mouse model 
provides a unique opportunity to perform a targeted, systematic search through 
cholesterol regulatory pathways to find molecular targets for APP function in the absence 
and presence of stress to cholesterol regulation. 
In Specific Aim One, I use this mouse model to identify genes involved in brain 
cholesterol homeostasis regulated by APP. Depending on their genetic background, NPC 
mice begin to show symptoms six weeks after birth, with rapid decline until death around 
ten weeks (Nunes et al. 2011). In order to limit observed genetic changes to early factors, 
I proposed to perform genetic microarray analysis of cerebellum and cortex collected 
from pre-symptomatic mice (younger than six weeks) of the following genotypes: non-
functional NPC1 (Npc1-/-); lack of APP (Appko); double mutant carrying non-functional 
NPC1 and lacking APP (Appko/Npc1-/-), and wildtype controls. In addition to manual 
analysis, Ingenuity Pathway Analysis (IPA) software will be used to process the full 
dataset of gene expression changes and link them to common regulatory or functional 
pathways.  
I initially proposed to validate gene expression changes at the RNA and protein 
level using real-time quantitative PCR and Western blotting, respectively. Although 
ongoing work will utilize these approaches, they are replaced here by proteomic analysis 
using a shotgun approach, as this technique could potentially measure protein-level 
changes across thousands of proteins simultaneously. The approaches in this specific aim 
will test my hypothesis that APP regulates cholesterol pathways by gathering gene 
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expression information, with the goal of using any identified genes and pathways in the 
design of mechanistic experiments in Specific Aim Two. 
 
Results 
Initial Microarray Analysis Confirms Loss of APP Affects Expression 
of Genes in Cholesterol-Related Pathways 
Western blots for APP and NPC1 proteins were used by Nunes et al. to confirm 
the genotypes of the Appko, Npc1-/-, and Appko/Npc1-/- mice used for the microarray 
analysis (Nunes et al. 2011). I confirmed genotype identity as well in the samples that I 
used in order to rule out handling and/or labeling errors (not shown). I subsequently 
prepared cerebellum and cortex tissue for microarray processing (as described in 
Materials and Methods under Microarray Analysis) and received from GenUs Biosystems 
(Northbrook, IL) the list of gene expression levels across Appko and Npc1-/- genotypes. 
While the anatomical structure and known functions of cortex and cerebellum are 
dramatically different, it is reasonable to propose the study of a potential link of APP to 
cholesterol homeostasis in both regions. Their biological significance is evident: 
Cerebellum is the earliest and most affected tissue in the NPC brain; cortex is initially 
and severely affected in AD. In addition, Nunes et al. described widespread cholesterol 
and myelin dysregulation in both regions, suggesting that, despite their wide differences, 
there might be shared mechanisms of cholesterol homeostasis (Nunes et al. 2011).  
 
Cholesterol-Associated Genes Differentially Expressed in the Absence of APP: 
Cerebellum 
The list of genes that are involved in cholesterol biosynthesis and transport and 
are differentially expressed in cerebellum across Appko and Npc1-/- genotypes is presented 
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in table 1. Amongst them, the gene for 3-hydroxy-3-methylglutaryl-CoA reductase 
(HMGCR, http://www.ncbi.nlm.nih.gov/gene/3156), which is reduced in the Appko brain, 
is perhaps the most important, as it is the rate-limiting enzyme for cholesterol 
biosynthesis, it has been linked to AD, and it is regulated in part by Aβ (Grimm et al. 
2005; Grösgen et al. 2010).  HMGCR is not affected in the Npc1-/- brain, consistent with 
the idea that cholesterol impairment in Npc1-/- mice is primarily linked to transport 
defects. However, it is downregulated in Appko/Npc1-/- brains, confirming the impact of 
APP loss on the gene and suggesting that the exacerbated cholesterol phenotype seen in 
the double mutant brain may reflect in part the additive impact of HMGCR 
downregulation from APP loss and the trafficking defects seen in Npc1-/- mice. 
Other genes involved in cholesterol biosynthesis that are differentially expressed 
in the absence of APP are hydroxysteroid (17-beta) dehydrogenase 7 (HSD17B7, 
http://www.ncbi.nlm.nih.gov/gene/51478) and lanosterol synthase (LSS, 
http://www.ncbi.nlm.nih.gov/gene/4047). Hsd17b7 is a 3-ketosteroid reductase in the 
post-squalene biosynthesis of cholesterol and is downregulated in all non-control 
genotypes (Marijanovic et al. 2003). Double mutation of App and Npc1 has a greater 
effect on Hsd17b7 levels than loss of either gene alone. Lanosterol synthase is part of the 
biosynthetic pathway of lanosterol, which itself is an intermediate in cholesterol 
biosynthesis. It is not affected by the loss of Npc1, but shows a 2-fold decrease in its 
expression in Appko tissue that does not reach statistical significance (p=0.057). 
Nevertheless, this gene is of interest because loss of both App and Npc1 results in a 
significant reduction in its levels; therefore, it could contribute to the changes in 
cholesterol levels and distribution seen in the double mutant mice. Because lanosterol 
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Table 1. Genes of Interest Differentially Expressed in Mouse Cerebellum Samples. Statistically significant values (p < 0.05) are 
highlighted in dark green. 
 
Cerebellum 
  
Npc1-/- Appko Appko/Npc1-/- 
Gene Name Pathway Fold change p-value Fold change p-value Fold change p-value 
HMGCR Cholesterol Biosynthesis -1.52562 0.12834 -2.06016 0.03193 -1.92317 0.04882 
HSD17B7 Cholesterol Biosynthesis -1.48048 0.04894 -2.07897 0.02016 -2.20563 0.01523 
LSS Cholesterol Biosynthesis -1.59579 0.14351 -2.01464 0.05733 -2.75788 0.03432 
NSDHL Cholesterol Biosynthesis -1.25388 0.59047 -2.25352 0.13120 -2.51651 0.10028 
APOE Membrane Trafficking 1.44061 0.14494 1.10000 0.48902 2.25695 0.00160 
IDOL (Mylip) Membrane Trafficking 1.50719 0.06621 1.34162 0.01059 1.89959 0.00065 
LDLRAP1 Membrane Trafficking -1.20251 0.30474 -1.40333 0.00418 -1.71731 0.00938 
RAB15 Membrane Trafficking -1.06858 0.49950 -1.26104 0.04301 -1.33170 0.02615 
RAB28 Membrane Trafficking 1.17341 0.00686 1.22143 0.03559 1.34403 0.00255 
RAB3GAP1 Membrane Trafficking -1.02824 0.60069 1.62916 0.00145 1.68250 0.00603 
REP15 Membrane Trafficking -1.44421 0.04464 -1.94922 0.00121 -1.92215 0.00094 
VLDLR Membrane Trafficking -3.08933 0.00579 -2.69968 0.01007 -3.00601 0.00532 
VPS16 Membrane Trafficking 1.03588 0.42265 227.03531 0.00230 355.69361 0.00001 
VPS52 Membrane Trafficking -1.09767 0.84696 4.90361 0.00892 4.25163 0.00635 
ERMN Myelination -1.84502 0.05713 -1.94087 0.03265 -2.29073 0.01789 
OMG Myelination -1.12431 0.29316 1.59659 0.01396 1.77539 0.00360 
QK, v1 Myelination -1.38827 0.03758 -1.34727 0.00640 -1.42839 0.01764 
QK, v3 Myelination -1.24712 0.04122 -1.34609 0.01372 -1.26638 0.03987 
TSPAN2 Myelination -1.97175 0.01914 -1.81330 0.02248 -2.72712 0.00348 
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synthase has been shown to redistribute from the ER to mitochondria in a mouse model 
of Parkinson’s disease, further analysis to test the relevance of this gene will involve the 
study of intracellular redistribution changes in addition to measurement of its protein 
levels (Lim et al. 2012). 
Another pathway affected in the cerebellum in the absence of App involves 
membrane traffic throughout the endosomal/lysosomal membrane system, which is the 
key initial subcellular location affected by Npc1 mutations (Karten, Peake, and Vance 
2009). This pathway contains the gene most affected by the loss of App, vacuolar protein 
sorting homolog 16 (VPS16, http://www.ncbi.nlm.nih.gov/gene/64601), which is 
increased a remarkable 227-fold. While loss of Npc1 has no impact on Vps16, double 
loss of App and Npc1 leads to further increase of Vps16 to a final 355-fold. Vps16 is a 
component of the multivesicular body (multivesicular endosomes; MVB) and an essential 
regulatory element for endosome-lysosome fusion (Nickerson, Brett, and Merz 2009). 
Because MVB formation and dynamics depend on appropriate cholesterol homeostasis, 
changes in Vps16 levels may also contribute to the NPC phenotype exacerbated in double 
mutants – perhaps through a mechanism linked to aberrant endosomal formation and 
lysosomal cargo delivery (Brankatschk et al. 2011; Kobuna et al. 2010). Consistent with 
this concept, Vps52 (http://www.ncbi.nlm.nih.gov/gene/6293), which is required for 
traffic from endosomes to the trans-Golgi network, is significantly upregulated both in 
Appko and Appko/Npc1-/- brains. 
Furthermore, Rab proteins involved in endocytosis are also affected by the loss of 
App. Rab28 (http://www.ncbi.nlm.nih.gov/gene/9364), necessary for efficient turnover of 
endocytosed proteins and lysosomal delivery of cargo, increases in response to both Npc1 
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and App losses, an increase that appears to have an additive effect in double mutant mice 
(Stenmark and Olkkonen 2001). Rab3gap1 (http://www.ncbi.nlm.nih.gov/gene/22930), a 
Rab3 GTPase activating protein, is upregulated in Appko and Appko/Npc1-/- brains. This is 
a key finding because Rab3gap1 is expressed exclusively in the brain; mutations are 
linked to Warburg micro syndrome, a disease characterized by microcephaly and mental 
retardation (Morris-Rosendahl et al. 2010). Rab3gap1 is essential for neurotransmitter 
release through vesicular exocytosis, a part of the synaptic vesicle cycle that involves 
endocytosis and further recycling. In contrast, Rab15 
(http://www.ncbi.nlm.nih.gov/gene/376267), also exclusive to the brain and involved in 
early and recycling endosomal traffic, is downregulated in Appko brain; its effector, 
Rep15 (http://www.ncbi.nlm.nih.gov/gene/387849), decreases in response to single loss 
of App and Npc1, as well as in double mutants. 
In addition to genes involved in the basic mechanism of molecular transport 
through the endosomal/lysosomal system, I have identified genes that are specifically 
linked to cholesterol transport through this pathway. Of these, perhaps the most 
interesting is Mylip, also called IDOL, for Inducible Degrader Of the LDL receptor 
(IDOL, http://www.ncbi.nlm.nih.gov/gene/29116), which decreases in the absence of 
APP and is further downregulated in the double mutant brain. IDOL acts as a sterol-
dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and 
subsequent degradation of LDLR through a mechanism involving liver x receptors 
(LXRs) (Zelcer et al. 2009). Also of interest, low density lipoprotein receptor adapter 
protein 1 (LDLRAP1 or ARH, http://www.ncbi.nlm.nih.gov/gene/26119) decreases in 
Appko and Appko/Npc1-/- mice. Ldlrap1 is well known for its function in clathrin-mediated 
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endocytosis of low density lipoprotein receptors (LDLRs), so its downregulation, 
together with an increase in IDOL, could potentially affect cholesterol traffic through 
endosomes – a pathway that is already compromised in the NPC brain (Kang and Fölsch 
2011). 
Another key player in cholesterol transport in the brain is the previously-
mentioned apolipoprotein E (APOE, http://www.ncbi.nlm.nih.gov/gene/348), a 
significant risk factor for developing AD (Bu 2009). I found that, while it is not affected 
by the absence of either App or Npc1 separately, it is robustly upregulated in double 
mutant mice (2.25-fold; p=0.0016).  Furthermore, very low density lipoprotein receptor 
(VLDLR, http://www.ncbi.nlm.nih.gov/gene/7436), an ApoE receptor, is significantly 
downregulated across genotypes, indicating that both Npc1 and App roles are linked to 
this gene (Sakai et al. 2009). Interestingly, there is no additive effect in Appko/Npc1-/- 
mice, suggesting that they may function in the same pathway (Go and Mani 2012). 
Overall, it is evident that App loss correlates with widespread impairment of 
endosomal/lysosomal dynamics and cargo delivery, including cholesterol. Because these 
subcellular compartments, as well as the biological functions associated with them, are 
inherently affected in the NPC brain, loss of this novel APP role is likely to contribute to 
the exacerbation of the NPC phenotype seen in double mutant mice (Ganley and Pfeffer 
2006). 
I also explored the possibility that genes involved in myelination could be 
affected by APP function. Myelin contains large amounts of cholesterol and other lipids, 
while being essential to neuronal function, making pathways related to its formation and 
maintenance highly likely to be sensitive to cholesterol dysregulation. Identifying genes 
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affected by knocking out APP may help to explain the decreases in myelination and 
motor function in the Appko/Npc1-/- mice. Oligodendrocyte myelin glycoprotein (OMG, 
http://www.ncbi.nlm.nih.gov/gene/4974) is increased in samples from Appk o mice, but 
not Npc1-/- mice. This may fit with OMG being related to autoimmune reduction of 
myelination and the potential role of APP products, specifically Aβ, as anti-inflammatory 
in certain cases (D.-H. Lee and Linker 2012; Grant et al. 2012). 
Other myelination-associated genes that warrant further investigation include 
quaking (QK, http://www.ncbi.nlm.nih.gov/gene/19317), tetraspanin 2 (TSPAN2, 
http://www.ncbi.nlm.nih.gov/gene/10100), and ermin (ERMN, 
http://www.ncbi.nlm.nih.gov/gene/57471), all of which are downregulated in all three 
non-control genotypes. Quaking is part of a pathway that controls CNS myelination. 
TSPAN2 is still largely uncharacterized, but its similarity to other proteins suggests that it 
may be involved in oligodendrocyte differentiation into myelin-producing cells; its 
downregulation in Appko mice could affect myelin production. ERMN is involved in the 
late stages of myelinogenesis, as well as in myelin stability in the adult brain 
(Brockschnieder et al. 2006). 
 
Cholesterol-Associated Genes Differentially Expressed in the Absence of APP: Cortex 
Table 2 shows the genes that are differentially expressed in cortex across all three 
mouse genotypes. For the purpose of comparison, the genes differentially expressed in 
the cerebellum (table 1) are also included. The most striking observation is that the 
expression patterns of Vps16, Vps52 and Rab3gap1 show identical behavior in both 
cortex and cerebellum, in the absence of APP and regardless of Npc1 status. That these 
key players in the regulation of membrane traffic into endosomes, and through the 
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endosomal/lysosomal system, are equally affected in both tissues by the loss of APP 
suggests a novel function for APP in this pathway. 
Other genes involved in membrane or cholesterol traffic are not equally affected 
in both tissues. Indeed, of all the genes in these pathways identified in cerebellum that are 
responsive to APP, only VLDLR appears to be significantly reduced in double mutant 
mice in both brain regions; it is not reduced in the single mutants. Conversely, I found 
that only one additional gene involved in cholesterol biosynthesis appears to be affected 
by APP loss in the cortex: NSDHL (http://www.ncbi.nlm.nih.gov/gene/50814), an 
enzyme involved in post-lanosterol cholesterol biosynthesis (“NSDHL-Related Disorders 
- GeneReviewsTM - NCBI Bookshelf” 2012). The relatively few genes affected in the 
cortex is consistent with the observation that, in NPC, cholesterol dysregulation in cortex 
is less dramatic than in cerebellum (Treiber-Held et al. 2003). Nevertheless, further 
analysis will be necessary to determine whether these results reflect differences in 
cholesterol homeostasis between both tissues, or represent experimental artifacts.  
Another pathway of interest that shows similarities between both tissues is 
myelination. Table 2 shows that, similar to what occurs in cerebellum, OMG increases 
and TSPAN2 decreases in response to APP loss in both tissues, whereas QK and ERMN, 
both affected by APP loss in cerebellum, only increase in the cortex in double mutants. 
Further analysis of these genes at RNA and protein levels will help to determine whether 
they are physiologically linked to APP and/or NPC1 or if they represent experimental 
artifacts.
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Table 2. Genes of Interest Differentially Expressed in Mouse Cortex Samples. Statistically significant values (p < 0.05) are 
highlighted in dark green. 
 
Cortex 
  
Npc1-/- Appko Appko/Npc1-/- 
Gene Name Pathway Fold change p-value Fold change p-value Fold change p-value 
HMGCR Cholesterol Biosynthesis 1.28191 0.26695 -1.00172 0.99046 -1.19073 0.15375 
HSD17B7 Cholesterol Biosynthesis 1.15021 0.54615 -1.24442 0.38189 -1.06776 0.75585 
LSS Cholesterol Biosynthesis -1.07403 0.52298 -1.11832 0.60325 -1.40021 0.02441 
NSDHL Cholesterol Biosynthesis -1.08443 0.80681 -2.39082 0.00360 -2.42084 0.02924 
APOE Membrane Trafficking 1.33259 0.20150 1.07016 0.65921 1.37291 0.05622 
IDOL (Mylip) Membrane Trafficking 1.30666 0.00238 -1.19634 0.07663 -1.00697 0.74599 
LDLRAP1 Membrane Trafficking -1.36652 0.25243 -1.23575 0.39859 -1.50712 0.18871 
RAB15 Membrane Trafficking 1.14474 0.40199 1.26515 0.20115 1.18698 0.31115 
RAB28 Membrane Trafficking 1.00360 0.94732 1.02485 0.65331 -1.04156 0.71205 
RAB3GAP1 Membrane Trafficking -1.09915 0.37031 1.58579 0.00075 1.46309 0.00108 
REP15 Membrane Trafficking -1.08952 0.65337 1.10736 0.34906 -1.05510 0.53517 
VLDLR Membrane Trafficking -2.11742 0.15058 -1.45852 0.11242 -2.87415 0.01594 
VPS16 Membrane Trafficking 1.18982 0.34153 205.08349 0.00139 333.12936 0.00003 
VPS52 Membrane Trafficking -1.37708 0.54004 4.63975 0.01353 4.87509 0.01831 
ERMN Myelination -17.80916 0.00196 -1.97777 0.07195 -28.32791 0.00039 
OMG Myelination -1.07947 0.64051 2.14825 0.01465 1.90293 0.03231 
QK, v1 Myelination -1.21772 0.19489 -1.36811 0.08534 -1.51655 0.00008 
QK, v3 Myelination -1.25694 0.12463 1.01956 0.83774 -1.14664 0.21538 
TSPAN2 Myelination -8.70801 0.01797 -1.23509 0.58881 -11.25114 0.00346 
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IPA Analysis Connects Cholesterol Synthesis and Endocytosis 
Pathways 
More in-depth examination and discussion of pathways affected by removal of 
APP is possible using Ingenuity Pathway Analysis (IPA) software. This package draws 
from the body of published literature across diseases and model systems to suggest 
relationships between molecules. Gene expression changes observed via microarray can 
be overlaid on these relationships, allowing the researcher to infer potential systemic 
consequences as a result of the changes. Recalling that VLDLR is one of the membrane 
trafficking genes affected in the three mouse genotypes (table 1), I used IPA to find that a 
relationship between VLDLR and APP exists via reelin signaling. Expression changes in 
each genotype can be compared to infer how the combination of the Appko and Npc1-/- 
genotypes interact (figure 3). Although reelin is not directly affected by any of the 
genotypes, it appears from this network map that when the interaction of APP and reelin 
via ApoE is removed from the Npc1-/- mouse, downstream targets of VLDLR are also 
downregulated; these targets are not downregulated in either genotype alone. 
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Figure 3. Reelin-Related Interactions in Three Mouse Genotypes. Comparison of gene 
expression of genes related to reelin signaling among three mouse genotypes. In the 
Appko/Npc1-/- mouse (bottom), downstream targets of VLDLR are downregulated (red) 
that are unaffected (grey) by either genotype alone. 
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It is also interesting to see how changes in VLDLR, which I initially identified as 
belonging to membrane trafficking pathways (table 1), is related to other molecules and 
pathways via the broader pathway of lipid regulation. In this network, VLDLR 
(membrane trafficking) overlaps with cholesterol biosynthesis via HMGCR, both of 
which decrease expression as a consequence of APP loss (figure 4). IPA network maps 
highlight transcriptional changes in numerous other molecules that might otherwise be 
overlooked, including crossover with inflammatory molecules such as proinflammatory 
cytokines and CD59. CD59 relates to inflammation due to its function as a key inhibitor 
of cell lysis by complement, part of the innate immune system (Huang et al. 2006). CD59 
has been found to be decreased in expression in AD brains, and has been described as a 
potential target for therapeutic upregulation to inhibit pathological inflammation in the 
brain (Yang et al. 2000; Kolev et al. 2009). As can be seen in figure 4, although a number 
of the molecules that are downregulated in the Appko mice return to control expression 
levels in the Appko/Npc1-/- mice, CD59 expression remains down. At the same time, C1q, 
an initiator of the compliment activation cascade, increases expression, suggesting that 
some of the inflammatory pathology in these mice may be due to compliment activation 
(M. K. Zabel and Kirsch 2013) 
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Figure 4. Consequences of APP Loss on Lipid Regulation Pathways. Expression changes 
in the Appko and Appko/Npc1-/- mice relative to control mice are shown in green 
(increased), red (decreased), and gray (no change). Increased size highlights the notable 
molecules VLDLR, HMGCR, and CD59. 
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Using IPA to map a network in the Appko/Npc1-/- mice beginning with CD59, 
rather than VLDLR and lipid regulation, reveals a separate set of connections. In this 
map, shown in figure 5, CD59 is related to cholesterol biosynthesis via HSD17B7, 
previously highlighted in table 1. It is also related once again to lipid regulation through 
phosphatidylethanolamine N-methyltransferase (PEMT). PEMT, which is increased in 
these mice, is a protein involved in phospholipid metabolism; in cancer studies its 
increase is associated with pathological lipid metabolism and predicts shorter patient 
survival (Zinrajh et al. 2014).  
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Figure 5. Network Map of CD59 Relationships. Expression changes in the Appko/Npc1-/- 
mice relative to control mice are shown in green (increased expression) and red 
(decreased expression). Gray indicates no change relative to control. Increased size 
highlights CD59 and a gene involved in cholesterol biosynthesis, HSD17B7. 
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Finally, I used IPA to examine genetic relationships involving ERMN, a member 
of the myelination pathway of genes in table 1 (figure 6). Here, the network map shows 
an unexpected close connection between ERMN and APP expression, suggesting that 
there is a mechanistic, rather than simply consequential, relationship between APP 
expression and neuronal myelination. 
 
 46 
 
 
 
 
 
 
Figure 6. Network Map of ERMN-Related Genes.  Expression changes in the 
Appko/Npc1-/- mice relative to control mice are shown in green (increased expression) and 
red (decreased expression). Gray indicates no change relative to control. Increased size 
highlights ERMN and APP, which appear to share a mechanistic relationship. 
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These findings provide a solid basis for further mechanistic experiments in 
cultured cells (Specific Aim 2), which will help to separate bona fide changes from 
experimental artifacts and contribute to the understanding of what specific role APP has 
in endosome and cholesterol biology and how its loss may contribute to pathology. 
 
Proteomic Analysis 
For proteomic analysis, brain tissue samples were selected from mice of the same 
genotypes as those used for the microarray study: control, Appko, Npc1-/-, and  
Appko/Npc1-/-. Choosing different animals of the same genotype eliminates the possibility 
that overlap between the microarray and proteomic studies is limited to specific animals, 
strengthening the argument that any overlap between the microarray and proteomic 
datasets is a result of the genetic differences. 
Due to limitations in tissue availability, proteomic analysis could only be 
performed on tissue from the cerebellum, rather than both cortex and cerebellum as in the 
microarray analysis. Despite this limitation, it was likely that any observable changes at 
the pre-symptomatic stage would be the most apparent in this region: while at later stages 
the NPC phenotype affects large parts of the brain, the region most significantly affected 
at early stages is the cerebellum (Treiber-Held et al. 2003). 
To process samples for protein analysis, tissues were lysed according to standard 
protocol and a BCA assay used to determine the protein concentrations of each sample, 
diluting samples as necessary to equalize the concentrations. These samples were allowed 
to digest in trypsin, a serine protease that cleaves proteins between the amino acids lysine 
and arginine (Darbre 1986). Because of this well-documented activity, if a protein of 
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known sequence is digested by trypsin, the sequence can be re-assembled from individual 
peptide fragments based on where trypsin cleavage sites are located. 
After digesting the proteins into peptide fragments, the fragments from each 
animal sample were labeled with a six-plex series of tandem mass tags (TMT), a system 
of peptide labeling based on isobaric variation of an otherwise-identical structure (Dayon 
et al. 2008). Labeled peptides were combined into three sample sets, each containing 
proteins from four animals. These combined samples were subsequently divided into six 
fractions, based on pH, and the fractions analyzed by mass spectrometry. All copies of a 
single peptide are detected simultaneously, yielding a unique spectral signature that 
corresponds to the exact amino acid sequence of that peptide. This reading can be 
subdivided based on the TMT labeling, allowing for the calculation of a ratio between a 
given peptide sequence with one label (and thus from one sample) and the identical 
peptide sequence with one of the other five labels (and thus from a separate sample). 
Known peptide sequences and their mass spectrometry signatures are stored in a 
database that can be accessed using Thermo Proteome Discoverer (Thermo Fisher 
Scientific, Inc.), a software package that takes raw mass spectrometry data files as input 
and, using the SEQUEST algorithm, identifies possible peptide sequence signatures and 
searches for information on those signatures (and the possible proteins to which they 
belong) in the database (Eng, McCormack, and Yates 1994). These search results are 
presented as a list of identified peptide sequences and possible proteins. Proteins are 
assigned a confidence score based on the signal quality of the individual peptides and 
how many peptides of the whole protein were identified (“coverage”).  
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This data was inconclusive, potentially due to sub-optimal protein concentration 
in the samples analyzed; however, shown here is a representative sample of the data I was 
able to obtain (table 3). The table includes potential proteins that have a 20% or greater 
confidence of being accurate based on the number of times the protein was identified and 
the number of individual peptides found that belonged to that protein.  
My analysis did reveal apparent decreasing trends in glyceraldehyde-3-phosphate 
dehydrogenase expression (GAPDH) in the two APP knockout mouse genotypes (figure 
7, one-way ANOVA, 0.06 > p > 0.05). GAPDH catalyzes the conversion of 
glyceraldehyde-3-phosphate into glycerate 1,3-bisphosphate as part of glycolysis. 
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Table 3. Representative Sample of Proteomics Data. Values presented here are taken from the second set of tissue samples analyzed. 
 
 
Proteomics Data: Sample Set 2 
             
      
Npc1-/- 
 
Appko 
 
Npc1-/-/Appko 
    
Accession 
Number 
Description Score Coverage 
# 
Unique 
Peptides 
# 
Peptides 
(NPC 
130/wt 
131) 
Var. 
[%] 
(APP 128/wt 
131) 
Var. 
[%] 
(dKO 129/wt 
131) 
Var. 
[%] 
Var. 
[%] 
# 
AAs 
MW 
[kDa] 
Q8VCE0 
ATPase, Na+/K+ transporting, 
alpha 3 polypeptide OS=Mus 
musculus GN=Atp1a3 PE=2 SV=1 
- [Q8VCE0_MOUSE] 
62.1 21.56% 6 18 1.164 20.6 1.1012299 47.2 0.79734 30 9.4 1053 116 
Q03265 
ATP synthase subunit alpha, 
mitochondrial OS=Mus musculus 
GN=Atp5a1 PE=1 SV=1 - 
[ATPA_MOUSE] 
51.8 33.45% 7 14 0.994 14.6 1.08161045 94.4 0.747488 67.6 20 553 59.7 
P60202 
Myelin proteolipid protein 
OS=Mus musculus GN=Plp1 PE=1 
SV=2 - [MYPR_MOUSE] 
44.9 12.27% 2 4 0.378 13.9 0.39049587 61.6 0.369306 51.2 4.3 277 30.1 
Q6PIC6 
Sodium/potassium-transporting 
ATPase subunit alpha-3 OS=Mus 
musculus GN=Atp1a3 PE=1 SV=1 
- [AT1A3_MOUSE] 
43.2 10.07% 2 13 0.835 3.4 0.73503521 10.5 0.7515 15.9 2.4 1013 112 
P60202 
Myelin proteolipid protein 
OS=Mus musculus GN=Plp1 PE=1 
SV=2 - [MYPR_MOUSE] 
41.8 10.83% 2 3 0.522 28.3 0.5173439 129 0.508428 129 16 277 30.1 
Q04447 
Creatine kinase B-type OS=Mus 
musculus GN=Ckb PE=1 SV=1 - 
[KCRB_MOUSE] 
41.6 46.19% 6 13 0.95 11.1 1.10465116 47.8 0.73815 52.5 20 381 42.7 
Q7TMM9 
Tubulin beta-2A chain OS=Mus 
musculus GN=Tubb2a PE=1 SV=1 
- [TBB2A_MOUSE] 
36.1 21.57% 2 7 1.061 7.5 0.98605948 56.1 0.917765 54.7 18 445 49.9 
P52480 
Pyruvate kinase PKM OS=Mus 
musculus GN=Pkm PE=1 SV=4 - 
[KPYM_MOUSE] 
33.4 30.51% 5 12 1.229 11.1 1.09341637 25.2 0.997948 15.5 6.7 531 57.8 
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Q8VDN2 
Sodium/potassium-transporting 
ATPase subunit alpha-1 OS=Mus 
musculus GN=Atp1a1 PE=1 SV=1 
- [AT1A1_MOUSE] 
32.7 21.99% 2 16 0.986 5.3 1.26410256 18.4 0.927826 22.5 4 1023 113 
P60202 
Myelin proteolipid protein 
OS=Mus musculus GN=Plp1 PE=1 
SV=2 - [MYPR_MOUSE] 
30.8 11.19% 1 3 0.697 21.8 0.63363636 119 0.680272 112 7.3 277 30.1 
P16858 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Mus 
musculus GN=Gapdh PE=1 SV=2 - 
[G3P_MOUSE] 
30 25.83% 2 7 0.949 13.3 0.89867424 57.8 1.401673 38.3 12 333 35.8 
Q9ERD7 
Tubulin beta-3 chain OS=Mus 
musculus GN=Tubb3 PE=1 SV=1 - 
[TBB3_MOUSE] 
28.2 16.22% 1 6 1.259 13.2 1.04394693 4.5 0.985797 1.7 6.2 450 50.4 
P08551 
Neurofilament light polypeptide 
OS=Mus musculus GN=Nefl PE=1 
SV=5 - [NFL_MOUSE] 
26.7 10.68% 2 8 0.827 2.3 0.66747377 71 0.812114 25 1 543 61.5 
P99024 
Tubulin beta-5 chain OS=Mus 
musculus GN=Tubb5 PE=1 SV=1 - 
[TBB5_MOUSE] 
26.7 21.62% 1 7 0.828 
 
0.72887324 
 
0.369288 
  
444 49.6 
O08553 
Dihydropyrimidinase-related 
protein 2 OS=Mus musculus 
GN=Dpysl2 PE=1 SV=2 - 
[DPYL2_MOUSE] 
26.1 27.45% 4 10 0.966 11.5 0.92974013 12.1 0.754446 16.3 2.8 572 62.2 
D3Z6F5 
ATP synthase subunit alpha 
OS=Mus musculus GN=Atp5a1 
PE=3 SV=1 - [D3Z6F5_MOUSE] 
25.6 15.31% 2 11 1.005 12.8 1.09120521 5.8 1.18188 12.1 4.6 503 54.6 
D3YYN7 
Sodium/potassium-transporting 
ATPase subunit alpha-2 OS=Mus 
musculus GN=Atp1a2 PE=2 SV=1 
- [D3YYN7_MOUSE] 
25.6 10.56% 2 13 1.115 80.9 1.05288008 32.1 1.78177 34.4 2.1 947 104 
Q03265 
ATP synthase subunit alpha, 
mitochondrial OS=Mus musculus 
GN=Atp5a1 PE=1 SV=1 - 
[ATPA_MOUSE] 
24.8 9.95% 4 7 0.946 12 1.0836197 61.2 0.7568 73.2 19 553 59.7 
P68369 
Tubulin alpha-1A chain OS=Mus 
musculus GN=Tuba1a PE=1 SV=1 
- [TBA1A_MOUSE] 
23.5 23.06% 2 8 1.156 19.8 1.00960699 16.2 0.76296 19.2 36 451 50.1 
  
5
2
 
D3Z6F5 
ATP synthase subunit alpha 
OS=Mus musculus GN=Atp5a1 
PE=3 SV=1 - [D3Z6F5_MOUSE] 
23.3 11.73% 3 7 0.879 5.2 0.97234513 16.8 0.699684 12.6 14 503 54.6 
P56480 
ATP synthase subunit beta, 
mitochondrial OS=Mus musculus 
GN=Atp5b PE=1 SV=2 - 
[ATPB_MOUSE] 
22.1 34.40% 4 12 0.923 20.1 0.91840796 94.8 0.718094 66.2 8.7 529 56.3 
Q504P4 
Heat shock cognate 71 kDa 
protein OS=Mus musculus 
GN=Hspa8 PE=2 SV=1 - 
[Q504P4_MOUSE] 
22 26.00% 4 14 1.06 22.9 1.20317821 20.9 0.91054 20.4 29 627 68.7 
P51881 
ADP/ATP translocase 2 OS=Mus 
musculus GN=Slc25a5 PE=1 SV=3 
- [ADT2_MOUSE] 
21 13.09% 1 6 1.083 
 
1.13166144 
 
1.185885 
  
298 32.9 
Q9D6F9 
Tubulin beta-4A chain OS=Mus 
musculus GN=Tubb4a PE=1 SV=3 
- [TBB4A_MOUSE] 
20.1 22.97% 1 7 1.68 
 
1.32701422 
 
1.95552 
  
444 49.6 
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Figure 7. Relative GAPDH Expression. Graph of relative expression of GAPDH protein 
in three knockout mouse genotypes compared to expression of control mice. Both Appko 
and Appko/Npc1-/- mice have decreased GAPDH expression, while GADPH expression 
levels in Npc1-/- mice are comparable to that of controls. 
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Discussion 
My adaptive response hypothesis posits that APP functions as a critical regulatory 
molecule in the brain, responding to stresses that threaten the homeostasis of systems 
such as lipid metabolism. This hypothesized role for APP is supported by published work 
by Nunes et al using a mouse model: although loss of the App gene alone (Appko) 
appeared to have no significant effect on neurodegeneration, when it was combined with 
the loss-of-function Npc1 mutation (Npc1-/-), the pathological phenotype appeared both at 
an earlier time point and with more severe consequences than in the Npc1-/- mice. In 
addition to significant neurological pathology, measured by behavioral testing, the 
Appko/Npc1-/- mice showed increased cholesterol accumulation, inflammation, and tau 
phosphorylation compared to either mutation alone (Nunes et al. 2011). I expanded these 
findings, and strengthened the support of my hypothesis, by examining the molecular 
consequences of APP removal via transcriptomic and proteomic analysis. 
Microarray analysis allowed me to obtain a transcriptome for each mouse 
genotype, a dataset that formed the foundation of a search for mechanistic clues to why 
apparently small changes in cholesterol regulatory processes can have such a large 
impact.  Notably, the pathways affected in these severely degenerative double knockout 
mice fall into similar groups as those identified by human genome-wide association 
studies (GWAS) of AD patients: cholesterol synthesis, intracellular transport, 
endocytosis, myelination, and immune response (Waring and Rosenberg 2008; Naj et al. 
2011; Hollingworth et al. 2011; Jun et al. 2010). Transcriptomic analysis has also 
revealed interesting information supporting the observational data that APP function 
includes the regulation of cholesterol or cholesterol-related processes. APP loss alone is 
sufficient to cause gene expression changes in a number of pathways either directly 
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associated with cholesterol, such as synthesis and transport (HMGCR, LDLRAP1; tables 
1 and 2), and indirectly, such as those affecting myelination (ERMIN, TSPAN2; tables 1 
and 2). Using the IPA software reveals that altered cholesterol synthesis and transport 
genes VLDLR and HMGCR connect through the broader pathway of lipid regulation, 
which also connects to inflammation via CD59 (figures 5 and 5). APP may also have a 
mechanistic relationship to myelination through ERMN (figure 6). 
Unfortunately for the proteomic analysis, I made the post hoc discovery that my 
protein samples were not concentrated enough to give conclusive data. Although I 
worked closely with the LLU Mass Spectrometry core facility to prepare the samples 
according to their established protocol, it is possible that overall experience with 
preparing tissue samples for analysis was limited, as much of the previous work had been 
conducted using cell lysates (Xiong et al. 2011). My samples were also limited to small 
portions of mouse cerebellum, limiting my maximum possible protein concentration from 
the outset. Had I known in advance that protein concentration was an issue, I would have 
pooled several samples from identical mouse genotypes and performed fewer runs. In 
reviewing the literature, I also found that many techniques involve additional 
fractionation of the mixed protein samples using either a wider acidic gradient or 
isoelectric focusing (Xiong et al. 2011; Dayon et al. 2008; Licker et al. 2014). With 
increased fractionation, the likelihood that two different proteins are detected 
simultaneously is decreased, reducing background signal and making any changes in 
amount between animals more apparent. As a result of this experience, any future 
proteomic studies performed by the lab will have increased chance of success, and the 
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technique remains a valuable way to collect information on potential systemic changes 
between experimental groups. 
Despite the complications with the proteomics experiments, at least one protein of 
interest appeared to be decreased in both the APP knockout and the double knockout 
mouse genotypes: GAPDH. GAPDH is well known for its role in catalyzing one of the 
steps in glycolysis; however, what is most interesting about a change in GAPDH 
expression is the more recent association of the protein with oxidative stress. The 
molecule glutathione is critical for the elimination of reactive oxygen species (ROS). 
After this reaction takes place, glutathione is regenerated by a reaction with nicotinamide 
adenine dinucleotide phosphate (NADPH) (Rush et al. 1985). These reactions are 
important because under conditions of high oxidative stress, more NADPH is needed to 
continuously regenerate glutathione. Because this additional NADPH must be generated 
by metabolic pathways other than glycolysis, GADPH is involved in vesicular and axonal 
transport, the latter of which is likely crucial for neuronal function (Zala et al. 2013). 
GAPDH production is curtailed in order to force a shift in reactions in response to 
oxidative stress, and could also be occurring in the genetic knockout mice as part of the 
response to lipid dysregulation (Ralser et al. 2007; Agarwal et al. 2012). 
Data collected by microarray here was critical for establishing the biosimulation 
model described in the subsequent chapter. Additionally, the work I performed here 
provided validation that cholesterol systems were disrupted by the loss of APP even in 
the absence of an obvious phenotype, fully consistent with the APP role postulated by the 
adaptive response hypothesis. This finding will inform any future mechanistic study of 
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APP, as members of the cholesterol pathways can be used as reporters or specifically 
manipulated themselves.  
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CHAPTER THREE 
IDENTIFICATION OF SPECIFIC MECHANISMS THROUGH 
WHICH APP INFLUENCES CHOLESTEROL HOMEOSTASIS 
 
Specific Aim Two 
To identify specific mechanisms through which APP influences cholesterol 
homeostasis, I developed an in silico model in which to measure the systemic impact of 
manipulating APP on the cholesterol homeostasis pathways identified in SA1. Because 
entire molecular pathways can be observed in silico, this technique will reduce 
dependency on both in vitro and in vivo models for observation of system-wide 
consequences of genetic changes. 
 
Introduction 
In SA1 (discussed in the previous chapter), analysis of microarray and proteomic 
data in the APP and NPC1 mouse models highlighted functional pathways and interacting 
networks of genes and proteins that supported my hypothesis that APP regulates lipid 
homeostasis in the brain, especially in situations of cellular stress. In my original Specific 
Aim Two, I proposed to identify specific mechanisms through which APP influences 
cholesterol homeostasis in response to that stress. To achieve that goal, I had proposed to 
develop and validate an in vitro model in which lipid dysregulation could be induced, 
APP and its products manipulated, and the resulting consequences observed. In such a 
model, lipid dysregulation could take the form of loss of NPC1 function, inhibition of 
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HMGCR, or exposure to 27-hydroxycholesterol, an oxysterol that accumulates early in 
the AD brain (as discussed in chapter one). Manipulation of APP could be achieved 
through RNA interference or the use of secretase inhibitors.  
Figure 8A shows a schematic of such an experimental design, in which HMGCR 
inhibition by U18666A, or treatment with oxysterols in a variety of cell lines, with and 
without manipulation of APP function, is followed by measuring parameters related to 
cell stress and apoptosis (i.e. LDH release or filipin fluorescence), as well as the impact 
on signaling pathways identified in SA1 as being APP-dependent.   
However, while characterizing primary fibroblasts from NPC and AD patients, I 
obtained results that led to the modification of SA2. Specifically, I found that the 
intensity of filipin staining in NPC cells appeared to correlate with the severity of the 
NPC case, and that AD fibroblasts displayed increased baseline filipin staining relative to 
their age-matched controls. 
These findings suggested to me that filipin staining could reflect cellular damage 
linked to disease status. Furthermore, if that cellular damage were detectable at 
presymptomatic stages of AD, and its severity were to increase with disease progression, 
it might be possible to differentiate mild cognitive impairment (MCI) sufferers according 
to their risk of conversion into AD by monitoring filipin staining. Consequently, I shifted 
my focus from the original idea of using primary fibroblasts to test the in vitro role of 
APP in cholesterol homeostasis and explored instead the link between filipin 
fluorescence and cellular damage, to obtain proof of concept that filipin is not only 
associated wih an increase in cholesterol levels, but also can be used to measure cellular 
damage and by extension, disease status.  
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Figure 8. In vitro Testing of APP Mechanisms. A: Original experimental design for SA2. 
Stress to lipid regulation (U18666A, oxysterols) would be applied to cell culture models 
(fibroblasts, SH-SY5Y cells, peripheral blood mononuclear cells [PBMCs]) in which 
APP and NPC1 expression had been manipulated (using techniques such as siRNA 
knockdown and secretase inhibition). The resulting consequences to the cells would be 
observed by measuring cell death (LDH assays), the expression of proteins identified in 
SA1, and cholesterol accumulation (using filipin). B: Revised experimental design for 
SA2. In one set of experiments, cells are stressed and the impact of that stress measured 
using filipin. This design mechanistically links the stressor to an AD-like phenotype in 
cells. In a second set of experiments, individually assessing the impact of APP regulation 
on proteins of interest is replaced by in silico simulation, in which changes to APP and 
resulting impact can be simultaneously observed across every protein in a metabolic 
pathway. 
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Thus, my overall specific aim 2 was modified to include both the in vitro 
characterization of the link between filipin staining and cellular damage, as well as the 
generation of a biosimulation model to identify pathway-wide mechanisms through 
which APP influences cholesterol homeostasis. The modified experimental design is 
described in figure 8B. In order to find whether filipin intensity may be a marker of 
cellular damage, I measured the correlation between LDH release and levels of filipin 
fluorescence in the neuron-differentiated neuroblastoma SH-SY5Y cells following 
several cholesterol-associated stress stimuli.  
I specifically chose to assess the impact of side-chain oxidized cholesterols 24-
OHC and 27-OHC as forms of stress stimuli that are relevant to AD. Unlike cholesterol, 
27-OHC can cross the blood-brain barrier, and has been shown in SH-SY5Y cells to 
influence APP and Aβ production (Ghribi et al. 2006; Jaya Rantham Prabhakara 
Prasanthi et al. 2008; Jaya R. P. Prasanthi et al. 2009; Burg et al. 2013). Outside of the 
brain, oxysterols like 27-OHC activate liver x receptors (LXRs), which are also capable 
of regulating Aβ production (M. P. Burns et al. 2006; Jiang et al. 2008). Because it is 
physiologically capable of directly stressing neurons, and is known to be dysregulated in 
AD, treatment with physiologically relevant concentrations of 27-OHC is an ideal 
experimental stress stimulus (Shafaati et al. 2011). In order to control for any binding of 
filipin to oxysterols, I also treated cells with another oxysterol, 24-OHC. 24-OHC is the 
most prominent cholesterol metabolite in the brain and has been shown to have no effect 
on cells at equivalent doses to 27-OHC (Jaya Rantham Prabhakara Prasanthi et al. 2008; 
Jaya R. P. Prasanthi et al. 2009; Matsuda et al. 2013). 
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The second part of this aim is the setup of an in silico metabolic model using 
Transcriptome-to-Metabolome (TTM) biosimulation (figure 8B), a process developed by 
Phelix et al and initially tested on glycolysis in AD brains (Phelix et al. 2011). 
Leveraging the accumulated knowledge of biochemistry, TTM can generate a metabolic 
model based on gene transcription data. With the use of the model, entire metabolic 
pathways can be observed simultaneously, rather than the individual gene or protein 
changes identified by classical techniques. Recalling my initial goal in this aim of 
mechanistically characterizing the changes observed in SA1, TTM provides another 
method of re-creating the effects of APP and NPC1 manipulation, and offers a pathway-
wide perspective to generate predictions that can form the basis of a hypothesis for 
subsequent experiments. As highlighted in figure 8B, the serial work of stressing cells, 
manipulating APP expression, and measuring consequential protein changes could be 
performed in parallel. Rather than examining proteins identified in SA1 individually, 
TTM could test the effect of APP manipulation on all proteins in a pathway and show 
changes not only in proteins I had identified as significant, but also proteins that would 
have otherwise been overlooked. 
TTM simulations account for as many relevant reactions as can be practically 
included: the model of cholesterol metabolism that TTM uses to study the AD 
hippocampus has been published and includes fifty-one synthesis reactions and two 
degradation reactions – a total of fifty-three reactions (Christopher M Valdez et al. 2011). 
Each reaction is catalyzed by one or more enzymes that are themselves encoded by 
genes; the transcription values from the control microarray are used to apply a 
modification constant to each reaction. From this baseline model, percent changes in 
 64 
transcription as a result of disease or genotype are used to modify the constants. Thus, the 
metabolic consequences of the transcriptional changes can be visualized.  
Models generated by TTM should additionally be validated, by comparing 
predictions to metabolic information available in literature. In the specific case of the 
mouse model, it has been experimentally documented that free cholesterol accumulates in 
vesicles in brain tissue from the Npc-/- and Appko/Npc-/- mice (Nunes et al. 2011). If the in 
silico model does not also show this occurring, the simulation must be corrected 
accordingly. Refinement of the model is an ongoing process, especially given that many 
of the metabolic consequences in NPC involve abnormal localization rather than simply 
abnormal levels or synthesis (Vanier 1999). As well as adding additional reactions to the 
model, I, along with others in the Soriano and Phelix laboratories, are working to add 
compartmentalization and transport into the model. Subcellular compartments, such as 
the lysosome, would take the form of reaction groups that have limited input and output, 
while transport rate of metabolites between subcellular locations can be modeled as an 
additional type of reaction. Thus far, simulation results have shown unexpected metabolic 
alterations in the Appko mouse genotype. It is possible that these kinds of changes create a 
weakness to metabolic stress, such that the further addition of the Npc1-/-mutation causes 
such significant cellular distress (Nunes et al. 2011). 
In summary, the focus of my work has shifted from my original proposal of using 
an in vitro model to study the role of APP in modulating the cellular responses to 
cholesterol stress. Instead, the modified experimental setup presented here widens the 
scope of my aim, by exploring the possibility that filipin could be of potential value as a 
marker of cholesterol-induced cellular damage and disease status. In addition, TTM 
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allows testing the impact of APP manipulation on all the proteins within a full pathway, 
not only on proteins identified by microarray analysis as significant. 
 
Results 
Filipin Levels in Primary Fibroblasts 
Primary fibroblasts from AD, NPC, and DS patients obtained from Coriell Cell 
Repositories (table 4, chapter 6) were selected for their unique aspects as a means of 
testing my adaptive response hypothesis: AD cells as examples of the disease, NPC as a 
model of cholesterol dysregulation, and DS as a model of APP overexpression. Via 
Western blot, I confirmed the DS fibroblasts as a model of APP overexpression (figure 9, 
A), and confirmed that the increased Aβ production found in NPC brains is also active in 
fibroblasts, as evidenced by the presence of β-cleaved C-terminal fragment (CTF) of APP 
(figure 9, B) (Nixon 2004).  
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Figure 9. Fibroblast Western Blots. A, Western blot confirmed overexpression of full-
length APP in DS fibroblasts compared to age-matched controls. B, Western blot 
confirmed increased β-cleaved APP in NPC fibroblasts compared to age-matched 
controls. 
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I began the characterization of different cell lines by measuring intracellular 
levels of filipin in response to different cellular stressors. Using NPC fibroblasts as a 
model of cells that are constitutively under stress secondary to impaired cholesterol 
transport, I found that filipin staining in cells from a patient experiencing severe NPC 
symptoms at one year of age was more intense than staining in cells from a milder case of 
a twenty three year-old patient (figure 10), a finding that is consistent with reports of a 
spectrum of NPC disease phenotypes (Tängemo et al. 2011). This led to the intriguing 
possibility that filipin staining may correlate with cellular damage status and disease 
severity, rather than simply serving as a marker of cholesterol accumulation. I also found 
that AD fibroblasts had increased baseline filipin staining relative to their age-matched 
controls, a result that confirms observations that lipid abnormalities are a critical part of 
AD pathology and that these abnormalities are detectable even in peripheral cells (Pani, 
Mandas, et al. 2009; Pani, Dessì, et al. 2009; Mandas et al. 2012). Following up on this 
result, I repeated the experiment with additional AD patient and control fibroblasts from 
Coriell Repositories, and carried out a more objective quantification of results using 
fluorescence-activated cell sorting (FACS) analysis, in addition to the manual 
quantification of filipin fluorescence at the microscope. Unlike microscopy methods, 
FACS can quantitatively measure fluorescence in thousands of cells across numerous 
patients in a relatively short amount of time. As is clearly visible via fluorescence 
microscopy, and quantifiable by FACS, filipin fluorescence in fibroblasts from AD 
patients is higher than in age-matched control individuals (figure 11).  
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Figure 10. Filipin Staining of NPC Fibroblasts. Fibroblasts from patients with NPC 
symptoms at a young age (1 year) show more intense filipin staining than fibroblasts 
from patients with later onset of symptoms (23 years). All NPC fibroblasts have more 
filpin staining than their age-matched controls. 
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Figure 11. Filipin Staining of AD Fibroblasts. A, Control (top left) and AD (top right) 
fibroblasts were stained with filipin to visualize cholesterol abnormalities. Despite similar 
cellular densities, shown by transmitted light overlay, Alzheimer’s disease (AD) 
fibroblasts (bottom right) have a significant increase in filipin-positive cells compared 
control (bottom left). B, Flow cytometry quantitation of fibroblasts demonstrates a 
significant increase over baseline autofluoresence in each AD patient as compared to age-
matched control (one-way ANOVA, p = 0.01) 
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Filipin Levels and Cellular Damage in Differentiated SH-SY5Y Cells 
The finding that AD fibroblasts show filipin staining that is similar to that of NPC 
fibroblasts, without additional applied stress, suggested that filipin changes could be used 
as an indicator of AD-like cellular pathology. In accordance with my adaptive response 
hypothesis, I predicted that cholesterol stressors would be capable of inducing cellular 
damage and that this damage was being detected by filipin. Such a mechanistic 
demonstration would be in contrast to the thinking of the amyloid cascade hypothesis, 
which would suggest that the filipin staining in AD cells was a consequence related to Aβ 
pathology in the brain. 
For these experiments, healthy cells were needed so that filipin staining could be 
used to measure cellular damage as a consequence of stress. Rather than continuing to 
use control fibroblasts, I switched to SH-SY5Y neuroblastoma cells, which, when 
differentiated, have the cellular architecture of neurons (Encinas et al. 2000; Xie, Hu, and 
Li 2010). I used a more specific model stressor of lipid regulation in the brain, the side-
chain oxidized form of cholesterol, 27-hydroxycholesterol (27-OHC). Unlike cholesterol, 
27-OHC can cross the blood brain barrier, and has been shown in SH-SY5Y cells to 
influence APP and Aβ production (Ghribi et al. 2006; Jaya Rantham Prabhakara 
Prasanthi et al. 2008; Jaya R. P. Prasanthi et al. 2009; Burg et al. 2013). Using 27-OHC 
allowed me to test a mechanistic link between cholesterol-related stress and the filipin 
staining I had observed in AD fibroblasts, using a molecule with the physiological 
capability of causing damage, known abnormalities in actual AD, and in a cell culture 
model that was close to human neurons. As a positive control, I used the cholesterol 
synthesis inhibitor U18666A to generate filipin-detectable pathology analogous to what is 
observed in NPC cells. To control for the addition of oxysterols to the cells, I used 24-
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OHC, another oxidized form of cholesterol that has been shown to not be damaging to 
cells at equivalent concentrations (Jaya Rantham Prabhakara Prasanthi et al. 2008; Jaya 
R. P. Prasanthi et al. 2009).  
Using an assay for lactate dehydrogenase (LDH), I confirmed the detrimental 
effects of U18666A and 27-OHC on cell survival, compared to control and 24-OHC 
(figure 12, A). Quantifying filipin fluorescence with FACS, I found that 27-OHC, but not 
24-OHC, led to a statistically significant increase in filipin staining, comparable to the 
impact of U18666A (figure 12, B). Representative graphs of the FACS data show this 
increase in filipin fluorescence compared to control (shaded) cells (figure 12, C). Because 
the LDH assay showed that treatment also induced cell death, this confirmed that 
increased filipin staining was indeed a direct consequence of cellular damage. 
Additionally, the differential results with 27-OHC and 24-OHC treatment indicate that, in 
this neuronal model, filipin fluorescence does not correlate with overall levels of oxidized 
cholesterol, because the control oxysterol 24-OHC does not lead to significant changes in 
filipin signal. In support of my hypothesis, filipin fluorescence correlates with the cellular 
damage caused by 27-OHC and the positive control U18666A, which presents as changes 
in the subcellular distribution of free cholesterol and ganglioside GM1 that filpin detects 
(Arthur, Heinecke, and Seyfried 2011). 
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Figure 12. Effect of Oxysterols on Cell Survival and Filipin Staining. A, LDH assay 
shows that 27-OHC causes cell death comparable to that of the positive control, 
U18666A, while 24-OHC does not. B, Filipin increases in differentiated SH-SY5Y cells 
treated with 27-OHC but not with 24-OHC (one-way ANOVA, p = 0.01). 27-OHC, but 
not 24-OHC, appears to have a similar effect on cell survival and filipin staining as 
U18666A, a compound known to cause cholesterol and GM1 dysregulation. C, 
Representative flow cytometry histograms of differentiated SH-SY5Y cells treated with 
U18666A, 24-OHC, and 27-OHC. During analysis, a gate is set to include all cells to the 
immediate right of the peak fluorescence from control (shaded) cells; both control and 
experimental cells contained by this gate are considered filipin-positive. 
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TTM Biosimulation 
Using the datasets obtained from the microarray analysis described in SA1, gene 
expression values from control mice were used to assign constants to each reaction in the 
metabolic pathway for cholesterol synthesis. These constants were subsequently modified 
based on the percent change in gene expression, relative to control, found in the Appko, 
Npc1-/-, and Appko/Npc1-/- mice. Basic simulation results are visualized in figures 13, 14, 
and 15, where the cholesterol metabolic pathways are mapped with spheres indicating 
metabolites and arrows indicating reactions. Color and size indicate percent change in 
metabolite compared to control, with red indicating percent increases and green 
representing percent decreases. 
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Figure 13. Cholesterol Biosynthesis in Appko Mice. Metabolic network map of 
biosimulation results showing metabolic changes in Appko mice compared to control 
mice. Spheres represent metabolites, while arrows indicate reactions. Color and size of 
spheres represent percent difference over control; green represents the lowest (negative) 
percent differences while red represents the highest (positive) percent differences.  
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Figure 14. Cholesterol Biosynthesis in Npc1-/- Mice. Metabolic network map of 
biosimulation results showing metabolic changes in Npc1-/- mice compared to control 
mice. Spheres represent metabolites, while arrows indicate reactions. Color and size of 
spheres represent percent difference over control; green represents the lowest (negative) 
percent differences while red represents the highest (positive) percent differences.  
 
 
 
 77 
 
 
 
 
 
 
 
 
 
Figure 15. Cholesterol Biosynthesis in Appko/Npc1-/- Mice. Metabolic network map of 
biosimulation results showing metabolic changes in Appko/Npc1-/- mice compared to 
control mice. Spheres represent metabolites, while arrows indicate reactions. Color and 
size of spheres represent percent difference over control; green represents the lowest 
(negative) percent differences while red represents the highest (positive) percent 
differences.  
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The simulation model used to generate these figures is continually being refined 
to add additional detail that may more accurately represent the metabolic dynamics 
observed in AD. A large piece of this detail will be the addition of compartmentalized 
reactions, representing how many cellular reactions take place in specialized organelles, 
with metabolites transported between them. Within the simulation, compartments are 
modeled as groups of reactions with limited input and output, while transport steps are 
added as additional reactions. With these changes, I am specifically hoping to be able to 
model some of the reactions that take place in the lysosome, the organelle responsible for 
much of the intracellular cholesterol degradation reactions, and the stage at which most 
cholesterol accumulates in NPC (Vance 2006; Nixon 2004). 
 
Discussion 
In this chapter I have focused on identifying potential mechanisms through which 
APP might influence cholesterol homeostasis. Beginning with the information and 
experimental results I collected in SA1, I have tried to link the pieces together in a way 
that allows for the formation and testing of hypotheses. As there continues to be a dearth 
of mechanistic information on AD, any insight I am able to find represents a potential 
avenue for earlier identification of disease risk, or even future intervention strategies. 
Importantly, during my work on this aim I found that filipin staining could be used as an 
indicator of the cellular damage that occurs in AD. On a basic science level, this 
repurposing of filipin staining provided a means to demonstrate that cellular stress 
stimuli, such as oxysterols, are capable of inducing AD-like cellular damage, which is of 
direct relevance to my adaptive response hypothesis. At the same time, I was able to 
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demonstrate the strong potential for filipin staining to be used clinically to diagnose AD 
risk. 
 
Filipin Fluorescence Correlates with Disease Severity 
Using NPC fibroblasts, I found that filipin staining in cells from a severely 
affected one year-old NPC patient was more intense than staining in cells from a less 
severely affected twenty three year-old NPC patient (figure 10). This finding is consistent 
with reports of a spectrum of NPC disease phenotypes (Tängemo et al. 2011). I also 
found, and quantified using FACS, that AD fibroblasts had increased baseline filipin 
staining relative to their age-matched controls (figure 11), a result that confirms 
observations that peripheral lipid abnormalities are a critical part of AD pathology (Pani, 
Mandas, et al. 2009; Pani, Dessì, et al. 2009; Mandas et al. 2012).  
 
27-OHC Treatment Produces AD-Like Filipin Fluorescence in 
Differentiated SH-SY5Y Cells 
Using differentiated SH-SY5Y cells as a neuronal model, I showed that the 
oxysterol 27-OHC, but not the oxysterol 24-OHC, is capable of inducing similar changes 
in cholesterol homeostasis to those observed in AD cells as well as changes artificially 
induced by U18666A (figure 12).  This experimental design allows me to conclude that  
filipin is detecting changes in cholesterol distribution caused by 27-OHC, a view 
supported by the fact that such changes also occur and are detected by filipin in NPC 
(Distl et al. 2003). This begins to build a picture of oxysterols having an impact on the 
brain, a picture supported by the fact that 27-OHC is one form of cholesterol that is 
capable of crossing the blood-brain-barrier and is elevated in AD brains (Ingemar 
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Björkhem 2012; Jaya R. P. Prasanthi et al. 2009; Shafaati et al. 2011; Leoni and Caccia 
2011). Thus, I have not only provided a potential mechanism by which systemic 
cholesterol abnormalities can cause stress in the brain, I have demonstrated for the first 
time that the damage caused by this stress can be detected and quantified using filipin and 
FACS. Ongoing work will continue to use this model to manipulate the expression of 
APP as originally proposed, and identify gene and protein-level changes. 
 
Biosimulation Validates Impact of APP Loss on Cholesterol 
Metabolism 
A large portion of my work in this aim involved using TTM biosimulation to 
leverage the gene transcription data collected in specific aim one, as well as the 
accumulated knowledge of biochemistry, to generate a metabolic model. Using 
biosimulation, complete metabolic pathways can be observed simultaneously prior to 
performing hands-on experiments with in vitro or in vivo models, rather than the 
individual gene or protein changes identified by more classical molecular approaches. 
Additionally, biosimulation provided another method of re-creating the effects of APP 
and NPC1 manipulation, supporting my aim of mechanistically characterizing the 
changes observed in SA1. 
Simulation of the interrelated endogenous cholesterol synthesis pathways showed, 
unsurprisingly, that mutation of Npc1 changes how this pathway is regulated (figure 14). 
I was surprised, however, to discover the extent of changes in this pathway due solely to 
the removal of APP (figure 13), especially since these mice appear functionally normal 
compared to their counterparts with the Npc1-/- mutation (Nunes et al. 2011). I previously 
noted, as part of my microarray analysis, that a number of genes were changed that fit 
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into a cholesterol metabolism pathway grouping (tables 1 and 2). On top of this, the 
simulation suggests that actual changes in the metabolic process are taking place that 
could lead to excess metabolites – metabolites that themselves could have detrimental 
effects. This finding is easier to visualize in a simplified presentation of the simulation 
data (figure 16). It is interesting to see here that the simulation predicts an increase in 
desmosterol, an immediate precursor to cholesterol that may have its own functions in 
myelination and brain development (Porter and Herman 2011; Herman 2003). 
This information begins to explain the surprising knock-on effect of combining 
APP knockout with NPC mutation in the Appko/Npc1-/- mice (Nunes et al. 2011). If APP 
is responsible, even in part, for the regulation of these pathways, it appears both from the 
mice and from the simulation that its importance is magnified when the pathway is under 
stress (figure 15). Without APP, an important protective mechanism is eliminated, 
causing stress damage from the NPC mutation to more rapidly cause negative 
consequences.  
Applied to human AD, it makes sense that a similar process might be underway as 
people age. As suggested by my hypothesis, metabolism, genetics, and environment all 
are able to cause varying levels of stress that can affect the brain. Action from APP is 
required to maintain a stable environment. Chronic stress over many years would prevent 
the APP mechanism from completely responding, and allowing damage to slowly build 
up until more severe consequences are noticeable. This would explain the appearance of 
APP products in high amounts in the brains of AD patients: evidence of a decades-long 
struggle to protect the brain from stressors. 
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Figure 16. Simplified Cholesterol Biosynthesis in Appko Mice. In this simplified 
representation of biosimulation results, metabolic changes in the cholesterol synthesis 
pathway are compared between APP knockout and control mice. Decreased expression of 
enzymes converting isopentenyl pyrophosphate (IPP) to cholesterol leads to an increase 
in the metabolite desmosterol. 
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In addition to the results already generated, the simulation model is continually 
being refined to add details, such as compartmentalized reactions, that will more 
represent metabolic dynamics with greater granularity. As the model becomes 
increasingly complete, more pathways are likely to emerge in which APP is central to 
cholesterol metabolism and transport. This will create more opportunities to test my 
hypothesis and may even suggest avenues for pharmacological intervention – 
interventions that may already exist as therapies for rare metabolic diseases. One way of 
visualizing the powerful aspect of simulation is shown in figure 17. Several post-squalene 
reactions in cholesterol synthesis are catalyzed by CYP51A1, an enzyme targeted by 
novel approaches to systemic cholesterol reduction that expand on what can be 
accomplished using statins (L. Zhang et al. 2012). This information would have been 
overlooked without the simulation, and, hypothetically, a validated technique for altering 
cholesterol (like targeting CYP51A1) could become a useful manipulation technique for 
experimentally characterizing APP mechanisms, and could even be a possible means of 
treating AD abnormalities. 
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Figure 17. TTM Biosimulation Uncovers Possible Experimental Approaches. CYP51A1 
has been targeted as part of a unique approach to reducing systemic cholesterol levels. 
Such an approach could be repurposed in the laboratory as part of experiments designed 
to better characterize APP function, or even become new AD therapies. 
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CHAPTER FOUR 
CONFIRMATION OF CLINICAL RELEVANCE AND 
PRACTICAL APPLICATION OF APP-CHOLESTEROL 
RELATIONSHIPS IN THE BRAIN 
 
Specific Aim Three 
To determine if filipin levels can be used as potential predictors of Alzheimer’s 
disease risk, I tested whether filipin intensity correlates with dementia status in peripheral 
blood mononuclear cells and B-lymphocytes obtained from AD patients. 
 
Introduction 
Results gathered in Specific Aims One and Two are significant on a basic science 
level, especially as they contribute to testing a hypothesis of AD that, unlike the amyloid 
cascade hypothesis, has the potential to guide researchers toward novel therapeutic 
approaches. However, the genetic and mechanistic work of the previous two aims relies 
heavily on model systems. Demonstrating that these findings are reflective of human AD 
validates the significance of the work as a contribution to the scientific understanding of 
the disease. I have utilized the results from my hypothesis testing in the design of two 
potential tests for AD risk, which has yielded an exciting opportunity to promote the 
clinical application of basic science findings.  
Initially, this third specific aim was centered on the validation of my molecular 
findings in human brain tissue. However, the work on SA1 (presented in chapter two) 
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provided a strong confirmation of the hypothesis that APP is part of an adaptive response 
to stress in the brain, identifying networks of genes involved in processes such as lipid 
regulation and transport that are disrupted when APP is removed. A prediction of this 
hypothesis is that lipid dysregulation will occur, and become apparent, in the AD process 
well before dementia symptoms.  
My work in cultured cells for SA2, presented in chapter three, demonstrated that 
peripheral cells of AD patients show severe lipid abnormalities that can be detected using 
filipin, a compound used to detect similar abnormalities in the diagnosis of other diseases 
such as NPC (Arthur, Heinecke, and Seyfried 2011; Argoff et al. 1990; Karten, Peake, 
and Vance 2009; Tängemo et al. 2011). My mechanistic work in neuron-like 
differentiated SH-SY5Y cells showed that 27-OHC, an oxidized form of cholesterol that 
has been shown to stress cells and is upregulated in AD, is capable of inducing similar 
abnormalities that can also be detected using filipin (Jaya R. P. Prasanthi et al. 2009; Jaya 
Rantham Prabhakara Prasanthi et al. 2008; Shafaati et al. 2011). 
In this chapter, I synthesized this information in the design of a potential test for 
AD risk, using filipin to detect lipid abnormalities in peripheral cells. My rationale for 
this approach was that both my adaptive response hypothesis, as well as the results from 
the first two specific aims, support the prediction that lipid abnormalities can be 
identified prior to dementia symptoms. If this were the case, testing for these 
abnormalities would allow patients to seek further advice from a neurologist or be placed 
into trials for experimental MCI and AD interventions. A clinical study to test this 
prediction is ideal; however, collection of fibroblasts requires an invasive punch biopsy, 
while differentiating neurons from individual patients is time and cost prohibitive. Before 
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a clinical study could be proposed and approved, I needed to demonstrate that the idea 
could be tested on patients in a non-invasive manner. In order to work toward clinical 
validation of a filipin-based test for AD risk, I showed that PBMCs are capable of 
showing similar filipin fluorescence to what was observed in fibroblasts, and that there 
are distinct differences in filipin fluorescence between B-lymphocytes (a subset of 
PBMCs) from control and AD patients. At the same time, I worked on a separate non-
invasive test for AD risk based on observations that movement abnormalities may occur 
early in the disease. This test utilizes the Myo, a commercial computer input device that 
is capable of detecting both physical movement and electrical signals from muscles 
(Digman 2014; Etherington 2014). Both tests have been granted provisional patents, and 
the clinical study of the filipin test is underway.  
 
Results 
Filipin Levels in Human Brain 
I initially used filipin to stain human brain tissue samples kindly provided by Dr. 
Kirsch here at LLU, with the goal of measuring a potential correlation between the 
patterns of distribution and intensity of filipin staining and dementia status. 
Unfortunately, while some filipin fluorescence was visible, the areas of staining did not 
conform to cellular boundaries. Instead, it appeared that filipin was labeling lipids 
associated with A plaques in affected tissue, and did not label intracellular lipids in 
either control or AD patients. Given the inconclusive results with brain samples, I began 
to focus on cellular models that could provide information regarding the potential 
correlation of filipin intensity and dementia status.  
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Cholesterol Dysregulation in Peripheral Blood Mononuclear Cells 
In order to more readily test the clinical applications of my findings with filipin, 
described in the previous chapter, I needed to determine first if peripheral blood cells 
(PBMCs) displayed the range of cholesterol levels that is subject to dysregulation, as I 
showed with fibroblasts and SH-SY5Y cells. The rationale for this initial test is that, if 
such a range were not present, there would be no obvious basis for the study of 
cholesterol dysregulation in these cells. Furthermore, such testing is also important 
because PBMCs consist of dozens of cellular subtypes. That complexity is potentially 
advantageous, both in providing mechanistic insight into the system-wide pathology of 
AD that disproportionally affects cognitive function (as each subtype is functionally 
defined) and to fine-tune potential clinical tests based on these cells.  
To test the susceptibility of PBMCs to cholesterol dysregulation, I treated human 
PBMCs with U18666A. Figure 18 shows a dose-dependent effect of this HMGCR 
inhibitor on filipin staining, confirming that cholesterol dysregulation can be induced in 
PBMCs (figure 18, A). Representative FACS histograms (figure 18, B) reflect this 
increase in filipin fluorescence over control (shaded) cells. 
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Figure 18. Cholesterol Dysregulation in Human PBMCs. A, Human peripheral blood 
mononuclear cells (PBMCs) treated with increasing concentrations of U18666A to 
induce cholesterol and GM1 dysregulation also show a dose-dependent increase in the 
percentage of filipin-positive cells, indicating that PBMCs are also sensitive to 
dysregulation visible via filipin staining (one-way ANOVA, p = 0.03). B, Representative 
flow cytometry histograms of PBMCs treated with U18666A. During analysis, a gate is 
set to include all cells to the immediate right of the peak fluorescence from control 
(shaded) cells; both control and experimental cells contained by this gate are considered 
filipin-positive. 
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Next, I asked whether cholesterol dysfunction is present in PBMCs from AD 
patients, as such occurrence would be consistent with cholesterol-associated cell damage 
correlating with cognitive status, while providing strong justification for the initiation of 
a longitudinal clinical study to test the predictive value of filipin. Using FACS, I 
measured filipin fluorescence in B-lymphocytes from AD patients and appropriate 
controls purchased from Coriell cell repository (table 4, chapter 6). A significantly larger 
proportion of filipin-positive B-lymphocytes occurs in AD patients as compared to 
controls, again consistent with the concept that there is a continuum of cholesterol-
associated damage in these cells as the disease progresses that is detectable by filipin 
(figure 19, A). Additionally, I determined the average mean fluorescence intensity in 
individual cells, as a measure of the severity of intracellular abnormalities (figure 19, B). 
Figure 19B shows a dramatic, significant increase in that average, indicating that B-
lymphocytes populations from AD patients not only show larger numbers of filipin-
positive cells, but also display greater severity of intracellular, filipin-measurable 
abnormalities. A representative flow cytometry histogram (figure 19, C) shows the 
increased filipin fluorescence in AD B-lymphocytes compared to control (shaded) cells. 
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Figure 19. Filipin Staining of B-Lymphocytes. A, Flow cytometry analysis of B-
lymphocytes from control and Alzheimer’s disease (AD) patients shows that AD cells 
show a significantly higher percentage of filipin-positive cells (two-tailed t-test, p = 
0.01). B, Mean filipin fluorescence intensity of B-lymphocytes is significantly increased 
in AD patients compared to control (two-tailed t-test, p = 0.02). C, Representative flow 
cytometry histogram of B-lymphocytes. During analysis, a gate is set to include all cells 
to the immediate right of the peak fluorescence from control (shaded) cells; both control 
and AD cells contained by this gate are considered filipin-positive. 
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Myo-Parkinson’s Project 
This project applies my theoretical breakthroughs in Alzheimer’s disease to a new 
area of research. With the previous patent project, I was looking for an early signal of AD 
that could be objectively defined and used to develop a risk threshold; filipin staining 
filled this role.  When I first encountered the Myo device, I saw an opportunity to collect 
more detailed movement data than ever before, which suggested that a similar approach 
could be used to objectively define thresholds based on tremor, an idea that has 
immediate application to Parkinson’s disease (PD). Of greater relevance to my work on 
AD, it has been documented for some time that AD develops motor abnormalities in later 
stages (Parakh et al. 2004; Nishikata et al. 2013). More recently, imaging studies have 
presented evidence that areas of the brain involved in coordinating motor actions are 
affected at early stages (Schroeter et al. 2009; Jacobs et al. 2011). These findings 
suggested to me that small movement abnormalities could be beneficial as an early sign 
of AD. Several studies using specific motor testing or simple accelerometer-based 
actigraphy have already shown that a motor-based test is capable of differentiating MCI 
patients from healthy controls of similar age (Hawkins and Sergio 2014; Kirste et al. 
2014).  
Given the high sensitivity of the Myo for movement and muscular activity, it 
seems plausible that patients could be asked to wear the device for a specific length of 
time, or perform a series of actions while visiting their physician, and subsequently 
analyze the collected data for patterns associated with cognitive dysfunction. A system 
such as this (concept shown in figure 20) has the potential to detect these signs earlier 
than other available testing methods, and is similar to my work on the filipin test in that it 
attempts to find ways to generate a reliable signal that can be analyzed as objectively as 
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possible to separate low-risk and high-risk MCI patients. Ideally, with early detection, 
high-risk patients can be entered into clinical trials for pharmacological approaches, or 
make lifestyle changes before additional irreversible damage occurs. 
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Figure 20. Concept for Detection of Movement Abnormalities Using Myo Device. 1) 
Movements from individual control and Parkinson’s patients are recorded using the Myo 
device produced by Thalmic Labs, Inc. 2) Raw data on motion and muscular activity is 
collected from the device. 3) Raw data is processed using a signal-noise isolation 
algorithm to identify distinct patterns produced by individuals with tremor. 4) Identified 
tremor patterns are recorded. 5) Data collected from many patients using the Myo device 
is processed and compared against previously identified tremor patterns. 6) The process 
correctly identifies individuals with and without tremor. 
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I immediately took the lead on this project and began making the necessary 
contacts at Thalmic, the company developing the Myo device. I was able to file a 
provisional patent on the concept which has since been approved. I filed a grant 
application to use the Myo in a study of essential tremor, the most common form of 
tremor. In discussions with LLU neurologists, the possible applications for Myo data 
were expanded beyond tremor alone to include even earlier markers such as asymmetrical 
movement. Currently this project is in the process of securing working legal agreements 
between LLU and Thalmic, after which special-access editions of the devices will be 
made available for our research. 
 
Discussion 
In this chapter I took the molecular mechanistic insight from the preceding two 
chapters and tested their clinical potential in human AD. This work has yielded the 
encouraging finding that the changes in cholesterol regulation highlighted by filipin 
staining persist even in the peripheral blood cells of AD patients. Using the HMGCR 
inhibitor U18666A to artificially create cholesterol abnormalities, I was able to 
demonstrate that cholesterol regulatory changes are detectable by filipin in peripheral 
blood cells isolated directly from human patients. Using lymphocytes from Coriell, I was 
able to show that the lymphocytes of AD patients have increased filipin staining, echoing 
my prior data in fibroblasts (presented in Specific Aim 1) and suggesting significant 
dysregulation of cholesterol-related processes in AD. This finding strengthens the 
argument that AD is, in fact, a systemic disease, and suggests – as my hypothesis predicts 
– that cholesterol regulation is a large part of the early disease process. The application of 
filipin as a potential early diagnostic for AD has been patented by the lab and limited 
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clinical trials are underway here at LLU. In these trials, I will be collecting peripheral 
blood cells from patients with MCI and staining with filipin. In this ongoing study, I will 
be able to determine if high filipin staining in MCI correlates with eventual conversion to 
AD, as well as verify my current findings that AD patients have significantly more filipin 
staining than normal controls of the same age. 
Navigating the process of filing a patent and designing a clinical test for the filipin 
study also allowed me to pursue a related idea using a new type of wearable sensor, the 
Myo. Using an “unlocked” developer version of the device, I will be working with 
several collaborators to analyze data captured by this device for signs of movement 
abnormalities, such as tremor, that could be early warning signs of Parkinson’s or other 
neurological diseases. This has also been patented and pending legal agreements between 
LLU and the manufacturer of the device will soon be tested on human patients. 
Participating in translational work is extremely rewarding for a student on an MD/PhD 
track such as myself: my doctoral work has given me the opportunity to not only add to 
the scientific understanding of AD, but also to develop applications with the potential to 
help those at risk of developing the disease.
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CHAPTER FIVE 
DISCUSSION 
Despite several decades of research, effective treatments for AD remain elusive. 
Numerous major clinical trials of potential AD therapies had failed as I began my 
doctoral work, with several more failing at phase three within the past year (Mullard 
2012; Karran and Hardy 2014; Karran, Mercken, and Strooper 2011). A common thread 
connecting all of these treatments is the amyloid cascade hypothesis, which implicates 
Aβ production and aggregation as causative to AD (J. A. Hardy and Higgins 1992). In 
addition to failing to produce workable clinical treatments for the disease, this hypothesis 
conspicuously omits any consideration of a physiological function for Aβ. Aβ is cleaved 
from the larger precursor protein, APP, the physiological importance of which was 
emphasized by the work of Nunes et al. In their work, Appko mice showed no obvious 
abnormalities, yet when this seemingly benign mutation was combined with the Npc1-/- 
mouse, the results were severe (Nunes et al. 2011). Npc1-/- mice model the human disease 
NPC, characterized by significant lipid accumulation in endosomes (Vanier 1999). At 
later stages, the disease also exhibits increased Aβ production and tau phosphorylation, 
both considered hallmarks of AD (Nixon 2004). In the combined Appko/Npc1-/- mice, the 
NPC phenotype appeared both more severely and at an earlier time point, with 
widespread inflammation in the brain, behavioral deficits, and increased tau 
phosphorylation (Nunes et al. 2011). 
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These observations, coupled with the failures of Aβ-centric therapeutic 
approaches, led me to incorporate the work of numerous other researchers into the 
adaptive response hypothesis, which suggests that APP is centrally involved in brain lipid 
regulation, especially in response to stress (Castello and Soriano 2013). In order to 
experimentally test this hypothesis, I first attempted to identify genes involved in 
cholesterol regulatory pathways that might be regulated by APP using microarray and 
proteomic analysis in Appko mice. Both of these techniques allow for the simultaneous 
consideration of thousands of genes and proteins, which allows for the observation of 
common pathways rather than a more limited focus on isolated changes. In performing 
analysis of the microarray dataset, I found that in the absence of APP, expression of 
genes involved in cholesterol regulation, endocytosis, and myelination pathways was 
altered (tables 1 and 2, figures 3, 4, 5, and 6), while analysis of proteomic data (table 3) 
suggested a change in expression of the metabolic enzyme GAPDH (figure 7). Taken 
together, these pieces of data begin to explain why the removal of APP in the mouse 
model of NPC was so severe: if APP is involved in the regulation of these pathways, their 
regulation is missing in the Appko/Npc1-/- mice. As a direct consequence, the brain is 
prevented from correcting ongoing imbalances and neurodegeneration progresses more 
rapidly (Nunes et al. 2011). 
In my second specific aim, I also demonstrated that filipin is a marker of 
cholesterol-associated cellular damage (figures 10, 11, and 12). This is a key novel 
finding because, although cholesterol-related abnormalities in peripheral cells of AD 
patients have been described (Pani et al. 2009; Mandas et al. 2012), it was previously 
unknown whether such abnormalities are reflective of pathogenesis or are instead a 
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marker for pleiotropic effects – an unanswered question with obvious implications for 
therapeutic intervention. Addressing that question, my finding that filipin fluorescence 
increased in response to 27-OHC (figure 12) cannot be accounted for by an overall 
increase in oxidized cholesterol levels per se, because an excess of 24-OHC, which is not 
cytotoxic, does not result in an increase in the filipin signal. In addition, I used the mouse 
microarray data and TTM biosimulation to construct a metabolic model of cholesterol 
metabolism. Using this model, I showed that loss of APP function causes significant 
abnormalities in cholesterol metabolism, including the accumulation of cholesterol 
intermediates (figures 13, 14, and 15). This information provides strong evidence in 
support of the argument that APP is a bona fide regulator of lipid metabolism.  
In my third specific aim, I began the foundational work of translating my 
laboratory findings into clinical applications. With the finding that filipin is a marker for 
cholesterol-associated cellular damage (figures 10 and 12), and the identification of 
filipin-sensitive lipid abnormalities in AD peripheral cells (figure 11), I designed a blood 
test for potential AD risk based on the premise that the abnormalities being measured 
begin at presymptomatic stages and therefore their clinical value is superior to that of the 
amyloid peptide Aβ (figures 18 and 19). 
 
APP is a Regulator of Brain Cholesterol Homeostasis 
While a relationship between cholesterol and AD has been repeatedly suggested, 
few researchers have focused on it as a useful source of information for the understanding 
and eventual treatment of AD. Initial insight into the cholesterol-APP relationship came 
from the mouse work by Nunes et al., which demonstrated that simply removing APP 
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from cholesterol-abnormal NPC mice was sufficient to increase both the severity and rate 
of decline of the pathology (Nunes et al. 2011).  
In SA1, microarray analysis revealed numerous transcriptional changes in 
networks of genes related to cholesterol and lipid synthesis, endocytosis, and even myelin 
formation (tables 1 and 2, figures 3, 4, 5, and 6). Many of these changes take place with 
APP knockout alone, and are compounded in an environment of severe stress such as that 
created by the loss of NPC1 function in the NPC mice. Proteomic analysis also revealed 
that APP knockout alone is sufficient to cause a decrease in GAPDH (table 3 and figure 
7), suggesting that a stress response pathway involving this metabolic enzyme is also 
affected by APP. These findings provide evidence for APP as a regulatory molecule 
capable of influencing metabolism, transport, and the use of lipids in tissues such as 
myelin. 
My work with biosimulation studies further confirmed a key role for APP in brain 
cholesterol metabolism by demonstrating significant widespread alterations in cholesterol 
synthesis pathways as a result of loss of APP function (figures 13, 14, and 15). Such an 
impact by APP on cholesterol metabolism suggests that while symptoms of dysfunction 
are not readily apparent in APP knockout mice (i.e. they do not have an overt phenotype), 
they are “primed” for more severe pathologies when subjected to biological stressors. If I 
had access to a colony of these mice, I would be interested in challenging them with a 
series of biological stressors. One such stressor might be the kind of high-fat diet used by 
Ghribi et al. in rabbit studies, while another might involve injection of a compound to 
destroy pancreatic islet cells, a technique used by Currais et al as a model of diabetes 
(Currais et al. 2012; Ghribi et al. 2006). These treatments attempt to model the kinds of 
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stressors that would be encountered by humans over the course of a lifetime, and which 
epidemiologically appear to confer some amount of AD risk. I would predict that in both 
of these cases, loss of APP would cause the brains of the mice to be more sensitive to the 
consequences of the stress. I would expect to observe increases in inflammation, as 
shown by GFAP, perhaps a decrease in lifespan compared to treated mice with a 
functional APP gene, and possibly even non-Aβ pathological hallmarks of AD, such as 
changes in brain cholesterol metabolism, loss of myelination, phosphorylation of tau, 
NFT formation, and ultimately neuronal loss. 
If these kinds of experiments continue to be performed, they represent a new 
avenue of pursuit for AD researchers. Cholesterol-related pathways have been 
independently studied for decades, and many compounds exist to manipulate various 
aspects of these pathways, either for the treatment of rare diseases or for more routine 
management of cholesterol levels. This suggests that pharmaceuticals already in 
existence could possibly be capable of treating AD at very early stages, prior to any 
measurable Aβ pathology (figures 16 and 17). Given the diversity of genes affected in the 
microarray (tables 1 and 2) as well as large-scale GWAS studies, it is also possible that 
individual patients could be profiled by microarray and the information used as the basis 
for TTM biosimulation. Biosimulation data would then identify the cholesterol pathways 
most at risk for future dysregulation, and treatment or lifestyle recommendations could be 
made immediately that may prevent or delay the onset of AD. 
Overall, the accumulated evidence shown here strongly supports my hypothesis 
that AD is in actuality a systemic disease that is detectable throughout the body. While 
the brain is the organ most sensitive to AD, signs of the pathology are apparent in the 
 103 
periphery, suggesting that identification of these signs, as well as intervention, could also 
be performed systemically. There is even the possibility that sustained changes in 
peripheral cholesterol regulation can positively affect AD risk, something strongly 
suggested by the observation that individuals who aggressively regulate high cholesterol 
in middle age are significantly less likely to develop AD decades later (Xu et al. 2011). 
 
Direct Clinical Application of Findings 
In SA2, I was able to successfully differentiate between AD and control 
fibroblasts on the basis of filipin staining (figure 11), I carried this research further to see 
if it had the potential to be used diagnostically. If cholesterol abnormalities are indeed as 
early in the AD process as I predict, such a test would be extremely useful for identifying 
at-risk patients and starting any potential interventions. While the fibroblasts study and 
FACS characterization described in SA2 (figure 11) was informative, the test would be 
far more clinically useful if it could be performed using blood cells. To that end, I first 
showed that filipin can be measured in PBMCs and that it displays a range of levels that 
corresponds to cholesterol dysregulation (figure 18). This offered proof of concept that 
PBMCs are of potential clinical use in filipin-based tests. Next, I used lymphocytes from 
AD and control patients (table 4), and successfully identified both populations based on 
their filipin levels (figure 19). It is also noteworthy that the choice of B-lymphocytes was 
determined by their commercial availability. Further work in larger clinical studies, 
which are already underway, will determine differences in filipin sensitivity between 
these cells and different subpopulations of PBMCs, which may show comparable or 
superior clinical value than B-lymphocytes to diagnose cognitive status and/or identify 
at-risk MCI populations. 
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The second clinical application I have been exploring involves using the Myo 
armband as a novel way of detecting and characterizing neuromuscular tremor, both in 
Parkinson’s disease patients and potentially as an early sign of AD (figure 20). This also 
represents a novel idea and I have been able to take the steps to translate it from concept 
to workable study over the past several years.  
In the future, I would like to see these two projects continue to move forward – 
the filipin study should also look at characterizing the types of cholesterol abnormalities 
with additional fluorophores, working toward the creation of a custom fluorophore to 
identify the most significant abnormalities as a replacement for the promiscuous staining 
patterns and volatility of filipin. With the Myo, I would like to see an expansion of the 
project to not only identify tremor signals, but isolate them from user input to a computer. 
In this way the device can be not only diagnostic, but also interventional, improving 
quality of life for patients who are already suffering from severe movement impairment. 
 
Supporting the Adaptive Response Hypothesis 
The results produced by the work presented here support the adaptive response 
hypothesis of AD I initially proposed (figure 2 and figure 21). Environmental factors 
ranging from metabolism, trauma, and neuronal activity combine to cause stress in the 
brain – stress that I replicated experimentally using Npc1-/- mice, which have a 
nonfunctional NPC1 protein (tables 1 and 2), and by treating cells with 27-OHC, a form 
of cholesterol that could physiologically link peripheral cholesterol dysregulation to the 
brain (figure 12). This stress prompts a response from APP that can be both functional 
and dysfunctional as it causes transcriptional changes in genes with lipid regulation, 
transport, and myelination function (here observed via transcriptomic analysis of APP 
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function in the mouse brain, tables 1 and 2) as well as altered cholesterol metabolism 
(predicted via biosimulation, as shown in SA2). My microarray data, as well as GWAS 
studies of AD patients, suggest that inflammation has a significant role in both functional 
and dysfunctional responses, perhaps due to connections between inflammation and APP 
(figures 3, 4, 5, and 6). In the event of a dysfunctional response, or when the stress is 
great enough to overwhelm the adaptive response driven by APP, disease occurs – which 
I observed in cells using filipin fluorescence (figure 11). In this disease state, other 
pathologies such as NFT formation and vascular Aβ deposition (CAA) are likely to 
occur, ultimately resulting in the death of neurons and loss of cognitive function. 
A major next step for testing my hypothesis will be to manipulate APP function 
under similar stress conditions to the ones I describe here. If APP levels are 
downregulated (i.e. via RNA interference), or its binding to cholesterol is inhibited, what 
are the transcriptional consequences? Are there measurable changes in filipin 
fluorescence? Conversely, if APP is overexpressed, or cholesterol metabolism prevented 
from changing, are cells more resistant to stress stimuli? These kinds of questions provide 
enormous opportunity to make use of both my in vitro and in silico work to gain greater 
mechanistic insight into AD. Ideally, this insight will lead to higher quality experimental 
design and therapeutic application in the AD field, which, unlike the current Aβ 
approaches, have a possibility of successful clinical outcomes. 
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Figure 21. Results from Testing the Adaptive Response Hypothesis. In this representation 
of the Adaptive Response Hypothesis, experimentally tested elements have been 
included. Non-functional NPC1 protein and 27-OHC were used as stressors (A), which 
tested a response from APP by observing transcriptional changes and altered cholesterol 
metabolism (B). Evidence of the disease state was found using filipin fluorescence (C), 
which greatly increased in response to stress. 
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Concluding Remarks 
In somewhat of a less-traditional path, I started my doctoral work with a large 
amount of theoretical research, attempting to assemble the collected pieces of information 
on APP and its relationship to AD. As a direct result, I was able to contribute my own 
hypothesis to the field beginning early in my career in the form of a published paper, 
followed by two more articles in which I drew attention to the shortcomings of the 
amyloid hypothesis and proposed viable alternatives to study the basic mechanisms of 
AD pathogenesis. Establishing a theoretical model also gave me a hypothesis-driven 
project, asking questions that could directly apply to the clinical understanding of AD. I 
was also able to publish results showing the potential clinical value of filipin in blood 
tests (Castello et al. 2014). 
Over the course of my PhD studies I have had to learn how to adapt my 
experimental goals to be more attainable or to work around setbacks, and in doing so 
have contributed at least a small part to my field of study by strengthening the argument 
for APP as a protein with cholesterol regulatory function. I am proud that my work has 
set up future opportunities for the lab to pursue, as the work of Dr. Ana Nunes did before 
me. Finally, I have tried to start the process of converting my discoveries into practical 
clinical applications, a project I hope to continue over the coming years. 
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CHAPTER SIX 
MATERIALS AND METHODS 
 
Introduction 
What follows is the complete documentation of the methods used to generate the 
presented data. Original sources are cited where possible, along with any modifications.  
 
Cell Culture 
Except where otherwise noted, cells were maintained in DMEM (fibroblasts, SH-
SY5Y) or RPMI (PBMCs, B-lymphocytes) with 15% FBS and 1% pen/strep and grown 
for experiments on 6-well or 24-well plates. 
 
Human Fibroblasts and B-Lymphocytes 
Human cell samples (fibroblasts and B-lymphocytes) were obtained from Coriell 
Institute for Medical Research (www.coriell.org). Fibroblasts were taken from patients 
with AD, Down syndrome (DS), NPC, and age-matched healthy controls, while B-
lymphocytes were taken from patients with AD and age-matched controls (table 4).  
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  Table 4. List of Cells Purchased from Coriell Cell Repository.  
 
Catalog ID Group Age Cell Type 
AG08243 AD 72 Fibroblast 
AG07375 AD 71 Fibroblast 
AG05770 AD 70 Fibroblast 
AG08245 Control 75 Fibroblast 
AG09019 Control 76 Fibroblast 
GM08333 Control 1 Fibroblast 
AG07804 Control 23 Fibroblast 
AG08942 DS 21 Fibroblast 
GM18436 NPC 1 Fibroblast 
GM17913 NPC 23 Fibroblast 
AG08526 AD 61 B-Lymphocyte 
AG21157 AD 61 B-Lymphocyte 
AG06204 AD 67 B-Lymphocyte 
AG21159 AD 69 B-Lymphocyte 
AG08242 AD 72 B-Lymphocyte 
AG10986 Control 82 B-Lymphocyte 
AG10955 Control 89 B-Lymphocyte 
AG08897 Control 61 B-Lymphocyte 
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Peripheral Blood Mononuclear Cells 
Peripheral blood mononuclear cells (PBMCs) from adult donors were obtained 
from Leuko-pak leukocyte filters (Fenwal Laboratories, Lake Zurich, IL) and donated by 
the Blood Processing and Quality Control Lifestream (San Bernardino, CA). Ficoll-
Hypaque (GE Healthcare, Pittsburgh, PA) and red blood cell lysis density gradient 
centrifugation were used to isolate PBMCs from blood collected from filters, as described 
(Tamul et al. 1995). 
For collection of PBMCs from AD patients, whole blood was collected by 
venipuncture in EDTA-treated collection tubes. 4 mL of whole blood was added to 20 
mL ammonium-chloride-potassium (ACK) lysing buffer and incubated 5 min at RT. 
Samples were centrifuged at 300 g for 5 min at RT, supernatant aspirated, and the pellet 
suspended in cold phosphate buffered saline (PBS). Peripheral blood cells were collected 
by centrifugation at 300 g for 5 min at 2-8 °C.  
For experimentation, PBMCs were cultured in a 96-well plate at a density of 400k 
cells per well. 
 
SH-SY5Y Cells 
SH-SY5Y human neuroblastoma cells (CRL-2266, American Type Culture 
Collection) were maintained in DMEM with 15% FBS and 1% pen/strep. Differentiation 
of SH-SY5Y cells was based on an established protocol involving sequential treatment of 
the culture with retinoic acid (RA) and brain-derived neurotrophic factor (BDNF), 
characterized by Encinas et al (Encinas et al. 2000). Cells were plated in plastic 6-well 
plates at 400,000 cells/well (day 1). After 24 hrs (day 2), media was changed to DMEM 
with 3.75% FBS, 1% pen/strep, and 10 µM retinoic acid (Sigma-Aldrich, St. Louis, MO). 
 111 
On day 5, media was discarded and replaced with fresh DMEM, again with 3.75% FBS, 
1% pen/strep, and 10 µM RA. On day 6, media was changed to DMEM without FBS, and 
containing 10 µM RA with 50 ng/mL of BDNF (Sigma-Aldrich, St. Louis, MO). 
Differentiated cells were experimentally treated on day 8. 
 
Immunofluorescence 
Preparation of Filipin 
Filipin was prepared as a 50 mg/mL solution in DMSO protected from light. 
Aliquots were stored in a light-protected container at -80 °C. Unused portions of thawed 
aliquots were discarded. 
 
Filipin Staining for FACS Analysis 
For FACS analysis, cells were fixed in paraformaldehyde (PFA) at room 
temperature (RT; fibroblasts and peripheral blood cells, 1% PFA 30 min at RT; B-
lymphocytes, 4% PFA 1 hr at RT) and treated with filipin for 30 min at RT (fibroblasts 
and peripheral blood cells, 50 μg/ml filipin; B-lymphocytes, 100 μg/ml filipin). 
 
Filipin Staining of Human Tissue 
Fixed post-mortem human brain tissue sections from patients with AD, vascular 
dementia, and an age-matched control were provided by the Kirsch lab. Prior to staining, 
sections were hydrated in increasingly dilute aqueous ethanol solutions, beginning with 
100% ethanol and ending with ethanol-free PBS. Sections were stained in 0.05 mg/mL 
filipin in PBS for one hour at RT, protected from light. 
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Filipin Staining and Immunofluorescence for Microscopy 
For fluorescence microscopy, filipin visualization, and measurements, cells were 
grown on glass coverslips and fixed in 4% PFA 15 min at RT. Filipin staining was 
carried out on fixed cells using 5 μg/ml of filipin (Sigma-Aldrich, St. Louis, MO) for 1 hr 
at RT in PBS + 1% BSA. 
Cells that had not been stained with filipin were blocked in 1% BSA 30 min at RT 
before treatment with primary antibody. Filipin-stained cells skipped additional blocking. 
Primary antibody at desired concentration was dispensed as a 50 μl droplet of antibody in 
PBS + 1% BSA solution on parafilm. Coverslips were placed facedown onto individual 
droplets and incubated in a humidified chamber 1 hr at RT. After incubation, coverslips 
were lifted off of the parafilm by adding additional PBS to droplets. Coverslips were 
washed in PBS three times for 5 min at RT. Addition of fluorescent secondary antibodies 
(Alexa fluorophores, Life Technologies) followed the same droplet procedure as for the 
primary antibody, while ensuring that the coverslips were protected from light during 
incubation. Cells were imaged on an EVOSfl fluorescence microscope (Advanced 
Microscopy Group) with excitation at 350 nm (filipin), 594 nm (red), or 488 nm (green). 
 
Flow Cytometry 
Flow cytometry was performed using a MACSQuant Analyzer (Miltenyi Biotec) 
with excitation at 350 nm. Average percentage of filipin-positive to total number of cells 
was calculated with FlowJo software (TreeStar, Inc.) using cut-off parameters based on 
cells from control patients (fibroblasts, B-lymphocytes) or treated with treatment vehicle 
(SH-SY5Y and peripheral blood cells). In all cases, control and experimental cell 
populations are first normalized to mode. A gate is set to include all cells to the 
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immediate right of the peak fluorescence from control cells; both control and 
experimental cells contained by this gate are considered filipin-positive. 
 
Microarray Analysis 
Brain tissue was collected from genotyped male and female mice between the 
ages of 6 and 13 weeks and flash-frozen in liquid nitrogen. Frozen samples were sent to 
GenUs (GenUs Biosystems, Northbrook, IL) to perform RNA extraction and microarray 
using the Agilent mouse v2 platform. Raw data received from GenUs was analyzed using 
Excel (Microsoft) and Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood 
City, CA). 
 
Transcriptome-to-Metabolome Biosimulation 
Initial Simulations 
Transcriptomic data acquired by microarray was processed for biosimulation in 
Excel by removing nonessential metadata, leaving only gene identifiers and raw 
expression values (as opposed to the relative expression values used to compare each 
mouse genotype to control). This data was converted into simulation values by the 
Transcriptome-to-Metabolome (TTM) algorithm maintained by Clyde Phelix and used by 
Phelix and others to analyze metabolic changes in AD brains (Phelix et al. 2011; Chris 
M. Valdez et al. 2010; Christopher M Valdez et al. 2011).  
Because the enzymes involved in catalyzing the reaction are known, the gene 
expression value for that enzyme can be used to modify the rate of reaction. A value, 
based on the gene expression of an enzyme, is added to the chemical reaction catalyzed 
by that enzyme as a constant. These values are initially configured using the gene 
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expression data from a control population, in this case the control mice. This set of 
reactions and constants forms a dataset that can be processed using the Complex Pathway 
Simulator software (COPASI), an open source biochemical network simulator (Hoops et 
al. 2006). Once any additional parameters such as length of simulation are set, COPASI 
simulates metabolic flux through the reactions, adjusting each reaction based on the 
constants, returning a new dataset of metabolites and their predicted amounts. 
Once the constants have been established to create a baseline model, the reaction 
constants are modified based on the percent change in gene expression that occurs 
between the control and experimental groups, allowing new simulations to be run and the 
resulting metabolite values compared between groups. Using Excel, the final dataset from 
COPASI can be imported into the Network Overview, Discovery, and Exploration for 
Excel (NodeXL) software, which is used to convert the raw numbers into a visual 
network map (Smith et al. 2010). 
 
Simulation Refinement 
After performing initial simulations using the above methods, the TTM model is 
refined by comparing the output with known metabolic outcomes. In the initial work by 
Phelix et al, simulations were compared with metabolic data for glycolysis products  
acquired from human brains (Phelix et al. 2011). TTM output was compared with what 
has been experimentally shown in the mice, such as the demonstration with filipin that 
free cholesterol accumulates in endosomes in both the Npc1-/- and  Appko/Npc1-/- mouse 
brains (Nunes et al. 2011). At this point, the gene expression-derived constants can be 
modified to better reflect the impact of transcriptional changes on metabolic output. 
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Additional reactions can be added to the overall simulation, or compartments can be 
simulated by limiting input and output of metabolites to groups of reactions.  
 
Preparation of Protein Lysates 
Tissue Lysis 
Fresh-frozen mouse tissue samples from cortex and cerebellum were 
microdissected and collected into Triton X-100 lysis buffer (1% Triton X-100, 150 mM 
sodium chloride, 50 mM tris pH 7.5 in dH2O) supplemented with protease inhibitor 
cocktail containing EDTA (Amresco, 1:100 from stock) and phosphatase inhibitors (10 
mM sodium fluoride, 2 mM sodium pyrophosphate, 1 mM sodium orthovanadate). 
Samples were sonicated until homogenous, centrifuged (15,000 rpm, 15 min, 4 °C), and 
the supernatant collected. Nuclear material remaining in the pellet was stored at -80 °C 
and lysed separately in RIPA lysis buffer (1% Triton X-100, 150 mM sodium chloride, 
50 mM tris pH 7.5, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS] in dH2O) 
with protease inhibitor cocktail and phosphatase inhibitors, sonicated, centrifuged 
(15,000 rpm, 15 min, 4 °C), and the supernatant collected. 
 
Cell Lysis 
To generate lysates from cells, culture plates were removed from incubator and 
immediately placed on ice. Media was removed and immediately frozen at -80 °C or 
discarded. Remaining cells were washed in PBS containing Ca2+ and Mg2+ and lysed for 
10 min in Triton X-100 lysis buffer containing protease inhibitor cocktail and 
phosphatase inhibitor compounds. Attached cells were scraped from plates and lysate was 
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collected and centrifuged. Supernatent was alliquoted and prepared for Western blotting, 
while the remaining pellet was frozen at -80 °C. 
 
Proteomic Analysis 
Trypsin Digestion and Isotope Labeling 
Protein was prepared for mass spectrometry according to a protocol established 
by Sowers et al in conjunction with the LLU Mass Spectrometry Core Facility (Xiong et 
al. 2011). Lysed mouse tissue samples were reduced with 1 M dithiothreitol (DTT) 1 hr 
at 50 °C. 0.5 M iododecamide was added and the samples incubated 2 hr at RT in the 
dark. 5 volumes of 100% acetone were added and the samples incubated overnight at -20 
°C. Samples were centrifuged (14,000 rpm for 10 min at 4 °C) and the acetone decanted. 
Remaining acetone was allowed to evaporate before adding 20 mM triethylamonium 
buffer (TEAB) and vortexing. Trypsin was added to the samples and allowed to digest 
overnight at 37 °C. Samples were centrifuged (14,000 rpm for 15 min at 4 °C) and the 
supernatant collected. A solution of acetonitrile (AcN) and one of six isobaric Tandem 
Mass Tags (Thermo) was added to each sample and incubated for 2 hr at RT. Reaction 
was quenched by incubating 15 min in 5% hydroxyamine at RT. Four of twelve total 
samples with different TMT tags were combined for fractionation to create three sample 
sets. 
 
Strong Cation Exchange Fractionation 
Strong cation exchange fractionation was performed by adding 1% formic acid 
(FA) to the combined labeled samples until pH reached 3-4 range. Strong cation 
exchange tips (TT1000 PSC TopTips, Poly LC) were prepared by passing 250 μl binding 
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solution (1% FA and 20% AcN) through the tip three times. Solutions were passed 
through the prepared tip and collected to generate individual fractions, beginning with the 
sample (flowthrough fraction) and followed by 0.05 M potassium chloride (KCl) in 20% 
AcN (fraction 1), 0.15 M KCl in 20% AcN (fraction 2), 0.3 M KCl in 20% AcN (fraction 
3), 0.5 M ammonium hydroxide in 20% AcN (fraction 4), and 50% AcN (fraction 5). At 
this point the tip was regenerated for repeated use by washing 3 times with 0.5 mL 5% 
ammonium hydroxide and three times with 1% FA. Samples were vacuum-dried 3 hr at 
RT and resuspended in 1% FA for desalting. 
 
Desalting 
Desalting tips (TopTip T1000 MC18 C18 gel-filtration, Poly LC) were prepared 
by washing three times with 1% FA. Each resuspended fraction was checked for a pH of 
3-4, passed through the prepared tip, and washed with 1% FA. Proteins were eluted by 
passing 60% AcN through the tip and collecting the flowthrough. Samples were vacuum-
dried, reconstituted in 0.1% FA, centrifuged (1 min 10,000 rpm) and transferred to tubes 
for mass spectrometry. Prepared fractions were run individually on a mass spectrometer 
by the LLU Mass Spectrometry core facility. 
 
Result Analysis 
Raw mass spectrometry data received from the LLU Mass Spectrometry core 
facility was imported into Thermo Proteome Discoverer™ (Thermo Fisher Scientific, 
Inc.) and searched against a database of known protein fragments using the published 
SEQUEST algorithm (Eng, McCormack, and Yates 1994). The resulting lists of 
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identified proteins and peptide sequences were exported to Excel (Microsoft) for further 
analysis.  
 
Statistical Analysis 
All statistical analysis was performed in SPSS Statistics (version 22, IBM Corp.) 
and Excel (2010, Microsoft). For single comparisons, homoscedasticity of variance was 
confirmed using an f-test and a two-tailed student’s t-test was performed. To compare 
more than one group to control and for comparison between groups, a one-way ANOVA 
was used with the Bonferroni post-hoc analysis. 
 
U18666A and Cholesterol Treatment 
Chemical Preparation 
U18666A was stored in aliquots at -80 °C as an aqueous solution at a 
concentration of 4.7163 M (2 mg/mL). Aliquots were diluted further in the appropriate 
culture media prior to treatment.  
24-hyrdoxycholesterol (24-OHC) and 27-hydroxycholesterol (27-OHC) were 
prepared as 10 mM solutions in 100% ethanol and stored in aliquots at -80 °C. Aliquots 
were diluted further in the appropriate culture media prior to treatment. 
Except where otherwise noticed, cells were treated with media containing 
approximately 5 mM U18666A, 10 M 24-OHC, or 10 M 27-OHC and incubated 
between 16-18 hours at 37 °C. This U18666A concentration is taken from its wide use in 
studies of NPC, while the cholesterol treatment concentrations are taken from work by 
Ghribi et al characterizing their effect in SH-SY5Y cells (Neufeld et al. 1999; Jaya 
Rantham Prabhakara Prasanthi et al. 2008; Jaya R. P. Prasanthi et al. 2009). 
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Cytotoxicity Assay 
Lactate Dehydrogenase (LDH) assays were purchased from Thermo Scientific 
(cat # 88953) and performed on plated cells according to the manufacturer’s instructions 
after treatment with 24-OHC (15 M), 27-OHC (15 M), or U18666A (300 M) for 12 
hours. LDH levels were quantified using a BioTek ELx800 plate reader. 
 
Western Blotting 
Lysate samples were prepared for running on tris-glycine gels (4-12% gradient, 4-
20% gradient, or 10-20% gradient, depending on the size of the proteins of interest) by 
combining with tris-glycine SDS sample buffer (2X, Life Technologies) and reducing 
agent (10X, Life Technologies). For tricine gels, sample was combined with tricine SDS 
sample buffer (2X, Life Technologies) and reducing agent. 
Equivalent volumes of sample were heated (tris-glycine: 10 min, 85 °C; tricine: 2 
min, 85 °C) and loaded onto the gels for separation (tris-glycine: 2.5 hr, 125 V; tricine: 
90 min, 125V) and transfer (tris-glycine: 30 min, 100V; tricine: 75 min, 75V) of proteins 
onto nitrocellulose membranes. Membranes were incubated in blocking solution (tris-
glycine: 5% milk in T-TBS; tricine: 5% BSA in T-TBS) 30 min at RT and incubated 
under parafilm overnight at 4 °C in the appropriate dilution of primary antibody 
(prepared in T-TBS). Membranes were washed in T-TBS three times for 10 min and 
incubated in the appropriate secondary antibody (1:15,000, Li-Cor) 1 hr at RT protected 
from light. After incubation, membranes were again washed in T-TBS three times for 10 
min, transferred to TBS, and imaged on an Odyssey scanner (Li-Cor). Intensity of bands 
was analyzed using ImageStudio (Li-Cor). 
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